var title_f20_7_20592="2D TTE parasternal long axis";
var content_f20_7_20592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) parasternal long axis view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This parasternal long axis echocardiogram was obtained in systole; the aortic valve is open and the mitral is closed.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; IVS: interventricular septum; NCC: noncoronary cusp of the aortic valve; PW: posterior left ventricle wall; RCC: right coronary cusp of the aortic valve; aML: anterior mitral valve leaflet; pML: posterior mitral valve leaftlet; dAo: descending aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20592=[""].join("\n");
var outline_f20_7_20592=null;
var title_f20_7_20593="Lymphangioleiomyomatosis CT";
var content_f20_7_20593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT scan demonstrates multiple thin-walled cystic airspaces of varying sizes, with loculated pneumothorax on the left (arrows) in a patient with pulmonary LAM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert S Crausman, MD and Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20593=[""].join("\n");
var outline_f20_7_20593=null;
var title_f20_7_20594="Alkali injury esophagus endoscopy";
var content_f20_7_20594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alkali injury to the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of caustic esophageal injury 24 hours after intentional ingestion of battery fluid (alkali) A: Proximal esophagus with superficial ulcers, bleeding and exudates (grade 2A) B: Distal esophagus with circumeferential ulcers and exudates (grade 2B) C: Gastric antrum with extensive necrosis and ulceration (grade 3B) D: Duodenum with mucosal edema and hyperemia (grade 1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George Triadafilopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20594=[""].join("\n");
var outline_f20_7_20594=null;
var title_f20_7_20595="Fat pad sign";
var content_f20_7_20595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Radiographic variations of the elbow fat pads",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     A)",
"    </strong>",
"    Normal relationships of the two fat pads.",
"    <strong>",
"     B)",
"    </strong>",
"    Displacement of both fat pads (arrows) with an intraarticular effusion.",
"    <strong>",
"     C)",
"    </strong>",
"    In some cases, the effusion may displace only the anterior fat pad (arrows).",
"    <strong>",
"     D)",
"    </strong>",
"    In extension, the posterior fat pad is normally displaced by the olecranon.",
"    <strong>",
"     E)",
"    </strong>",
"    An extraarticular fracture may lift the distal periosteum and displace the proximal portion of the posterior fat pad. (Redrawn from Murphy, WA, Siegel, MJ. Elbow fat pads with new signs and extended differential diagnosis. Radiology 1977; 124:656-659; with permission.)",
"    <strong>",
"     F)",
"    </strong>",
"    An x-ray showing displacement of both fat pads (arrows) from an intraarticular effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow region: General concepts in the pediatric patient. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20595=[""].join("\n");
var outline_f20_7_20595=null;
var title_f20_7_20596="Calcium phosphate, tribasic: Patient drug information";
var content_f20_7_20596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium phosphate, tribasic: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/58/21412?source=see_link\">",
"     see \"Calcium phosphate, tribasic: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/24/13701?source=see_link\">",
"     see \"Calcium phosphate, tribasic: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Posture&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, kidney stones, or low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron, zinc, or folic acid within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after a high bran or fiber meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soft, brittle bones (osteoporosis):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11308 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-32ABD8DF2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20596=[""].join("\n");
var outline_f20_7_20596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855584\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014194\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014193\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014198\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014199\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014201\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014196\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014197\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014202\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014203\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/58/21412?source=related_link\">",
"      Calcium phosphate, tribasic: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/24/13701?source=related_link\">",
"      Calcium phosphate, tribasic: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20597="Posaconazole: Patient drug information";
var content_f20_7_20597=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Posaconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     see \"Posaconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/18/35112?source=see_link\">",
"     see \"Posaconazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3339726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Noxafil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5222620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Posanol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to posaconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low magnesium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels or if you are taking a water pill, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you cannot take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High or low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11834 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20597=[""].join("\n");
var outline_f20_7_20597=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5222620\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028028\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028030\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028029\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028034\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028035\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028037\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028032\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028033\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028038\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028039\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=related_link\">",
"      Posaconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/18/35112?source=related_link\">",
"      Posaconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20598="Clonidine: Patient drug information";
var content_f20_7_20598=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clonidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     see \"Clonidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     see \"Clonidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Catapres-TTS&reg;-1;",
"     </li>",
"     <li>",
"      Catapres-TTS&reg;-2;",
"     </li>",
"     <li>",
"      Catapres-TTS&reg;-3;",
"     </li>",
"     <li>",
"      Catapres&reg;;",
"     </li>",
"     <li>",
"      Duraclon&reg;;",
"     </li>",
"     <li>",
"      Kapvay&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clonidine&reg;;",
"     </li>",
"     <li>",
"      Catapres&reg;;",
"     </li>",
"     <li>",
"      Dixarit&reg;;",
"     </li>",
"     <li>",
"      Dom-Clonidine;",
"     </li>",
"     <li>",
"      Novo-Clonidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691326",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control pain when infused into the spine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat drug addiction and withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691846",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hot flashes caused by other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rarely, it is used to treat loose stools having to do with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701840",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clonidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry eyes. Using artificial tears may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take last dose of the day at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3311838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Extended release tablets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off old patch first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the chest, back, or belly. Move the site with each new patch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch loosens, put tape over it to hold it in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed patch as soon as you think about it after taking off the old one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next patch, place the new patch on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start a new timetable after the patch is put back on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11609 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20598=[""].join("\n");
var outline_f20_7_20598=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153486\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023656\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023658\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023657\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023662\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023663\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023665\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023660\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023661\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023666\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023667\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=related_link\">",
"      Clonidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=related_link\">",
"      Clonidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20599="Pharmacotherapy for adult ADHD";
var content_f20_7_20599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for adult ADHD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20599/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20599/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20599/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20599/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20599/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20599/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/7/20599/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H102935206\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) was originally believed to be primarily a pediatric condition. However, the available data suggest that between 30 and 70 percent of children with ADHD continue to manifest symptoms in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulants, tricyclic antidepressants, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    are the most commonly used medications in adults with ADHD, but response rates may be lower in adults compared to children. Cognitive behavioral therapy (CBT) has been show to be efficacious in conjunction with medication.",
"   </p>",
"   <p>",
"    This topic addresses pharmacotherapy for adult ADHD. The epidemiology, pathogenesis, clinical manifestations, assessment, and diagnosis of adult ADHD are addressed separately. Psychotherapy for adult ADHD is discussed separately. ADHD in children is addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=see_link\">",
"     \"Adult attention deficit hyperactivity disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937177\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bulk of the available data on the treatment of ADHD are derived from studies in children, limiting the ability to make evidence-based recommendations for adults. Nonetheless, the use of medications to treat ADHD in adults has increased markedly in the United States (by 90 percent from 2002 to 2005), with adults receiving one third of all prescriptions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/5\">",
"     5",
"    </a>",
"    ]. This pattern is not seen in other countries.",
"   </p>",
"   <p>",
"    The mainstay of ADHD treatment is pharmacotherapy. Counseling and specific psychotherapies may be required to assist patients in restructuring dysfunctional life patterns while pharmacotherapy improves their ability to focus and organize their lives.",
"   </p>",
"   <p>",
"    Based upon the pathophysiologic mechanisms cited above, medications acting through the norepinephrine pathways of the CNS appear to most directly treat ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Stimulants are a major component of pharmacologic therapy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. For adults, stimulants and antidepressants (particularly those with norepinephrine activity) primarily have been used to treat ADHD. Doses for these medications are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef50379 \" href=\"UTD.htm?22/32/23054\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937184\">",
"    <span class=\"h1\">",
"     STIMULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants are the most commonly used medications in adults with ADHD. However, the addicting nature of stimulants, the chronicity of ADHD, and the large number of potentially comorbid conditions in adults have led some experts to recommend a trial of a nonstimulant agent first. Nevertheless, for the patient with no contraindications, long-term stimulant use is a reasonable choice for pharmacologic therapy.",
"   </p>",
"   <p>",
"    These agents stimulate the release of catecholamines from storage sites at CNS synapses; the exact focus of the pharmacologic effect is unclear. Increased norepinephrine and dopamine concentrations in the brainstem, midbrain, and frontal cortex have been postulated.",
"   </p>",
"   <p>",
"    The cognitive functions influenced by stimulants impact a number of daily living skills. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ingestion has been found to reduce driving errors in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/10\">",
"     10",
"    </a>",
"    ]. Stimulants may also produce these effects in patients without ADHD, and not all patients with ADHD improve with such therapy. Thus, the patient's response cannot be used to confirm or exclude the diagnosis of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulants are less effective in adults than in children with ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/12\">",
"     12",
"    </a>",
"    ]. Response rates in adults vary from 25 to 78 percent in the limited number of studies available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/13\">",
"     13",
"    </a>",
"    ]. This wide range reflects variability in diagnostic criteria, definitions of a positive response, drug dosing, and significant comorbidity among studied patients. Higher doses of stimulant medications are more effective than lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]; the highest response rate (78 percent) was achieved in a study that used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937191\">",
"    <span class=\"h2\">",
"     Stimulant preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of stimulant preparations are available, and differ in their pharmacokinetics, but have similar efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/17\">",
"     17",
"    </a>",
"    ]. Most contain racemic mixtures of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/7,16,18\">",
"     7,16,18",
"    </a>",
"    ], and are either short-acting (immediate release) or long-duration, formulated in wax matrix, beads, or osmotic-release preparations. A patch is also available. Because of delayed action, the methylphenidate patch should be applied two hours before its effect is needed.",
"   </p>",
"   <p>",
"    Other stimulants are amphetamines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ; a racemic mixture of d- and l-amphetamine (Adderall XR); and a prodrug of dextroamphetamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/53/23382?source=see_link\">",
"     lisdexamfetamine",
"    </a>",
"    (Vyvanse) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/20\">",
"     20",
"    </a>",
"    ]. As a prodrug, lisdexamfetamine may have lower abuse potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937198\">",
"    <span class=\"h2\">",
"     Cardiovascular side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular effects of stimulants are of potentially greater concern in adults than in children. Stimulants increase heart rate and blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a randomized study, blood pressure increase with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    averaged 5 mm Hg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/23\">",
"     23",
"    </a>",
"    ]. In response to reports of sudden death with use of stimulants in both adults and children treated for ADHD, the FDA has required that a patient medication guide be provided with dispensing of stimulants used for treatment of ADHD, describing cardiovascular risks (hypertension, cardiac arrest, arrhythmias, and stroke) and risks of adverse psychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/24\">",
"     24",
"    </a>",
"    ]. Blood pressure and heart rate should be closely monitored when initiating treatment with stimulants in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937205\">",
"    <span class=\"h2\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common initial side effect is sleep disturbance, characterized by delayed onset of sleep. This is also a common complaint of adults with untreated ADHD. Thus, it may be helpful to assess the patient's sleep patterns for several weeks if sleep problems develop after initiation of therapy, before altering the dosage or the timing of administration.",
"   </p>",
"   <p>",
"    Another side effect of stimulants may be a decrease in appetite resulting in weight loss. Stimulants can also cause the emergence of tics, which may be permanent in patients with a genetic or personal history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937212\">",
"    <span class=\"h2\">",
"     Abuse potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caution should be exercised both in making the diagnosis of ADHD and in avoiding the use of stimulants in patients with a history of substance abuse. For the patient with a history of substance abuse, a tricyclic antidepressant (TCA) that has activity through norepinephrine pathways (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    might be a preferred agent.",
"   </p>",
"   <p>",
"    The increase in extracellular dopamine that occurs with consumption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    is similar to the increase seen with use of cocaine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Oral methylphenidate does not cause a \"high\" because of the slow delivery to the brain when taken orally. However, injecting liquid methylphenidate can cause a high similar to that of cocaine.",
"   </p>",
"   <p>",
"    Adult patients may require larger dosages of stimulants than those prescribed to children. Thus, it is important to document the patient's symptoms and the response during dosage titration. Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    are C-II controlled substances, most states limit prescriptions to a 30-day supply and do not authorize refills. However, for chronic conditions such as ADHD, a 90-day supply may be authorized if the dosage regimen is stable. This requires frequent contact between the patient and clinician for reevaluation.",
"   </p>",
"   <p>",
"    The prodrug lisdexafetamine, which received US Federal Drug Administration approval for use in adults in 2008, may have lower abuse potential. A comparison of 100 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/53/23382?source=see_link\">",
"     lisdexamfetamine",
"    </a>",
"    and 40 mg immediate release d-amphetamine in subjects with a history of drug abuse found that subjective \"liking\" responses were significantly less for lisdexamfetamine; there was no difference, however, between 150 mg lisdexamfetamine and 40 mg immediate release d-amphetamine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937219\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants that inhibit reuptake of norepinephrine, and thereby increase the concentration of catecholamines in the CNS, have been evaluated for the treatment of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricyclic antidepressants (TCAs) inhibit the reuptake of norepinephrine and serotonin. The one available controlled trial of TCAs investigated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      (target dose 200 mg per day) in 41 adults with ADHD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/6\">",
"       6",
"      </a>",
"      ]. A response rate of 68 percent was noted in the desipramine group, compared to no response with placebo. The secondary amine TCAs, such as desipramine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      , may be preferred because of greater effects on norepinephrine than on serotonin and a better side effect profile than other TCAs. Because of the possibility of cardiac conduction abnormalities, an electrocardiogram should be obtained before initiating TCA therapy and after the dosage is stabilized.",
"     </li>",
"     <li>",
"      The response to selective serotonin reuptake inhibitors (SSRIs) has been less promising than TCAs in adults with ADHD, but the data are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/7,29\">",
"       7,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      , an atypical antidepressant with more stimulant properties than the TCAs, may be effective in adults with ADHD. Bupropion is a reasonable alternative treatment for patients with cardiac or other medical contraindications to stimulants or TCAs. Response rates to bupropion, in a range from 200 to 450 mg daily, varied between 53 and 76 percent in two studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. A positive effect on ADHD symptoms can be seen at two weeks after initiation of therapy.",
"     </li>",
"     <li>",
"      Therapy with monoamine oxidase (MAO) inhibitors has produced variable responses in patients with ADHD, but may be tried in patients who have responded poorly to other therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antidepressant therapy in adults with ADHD may be particularly helpful in reducing affective instability and controlling a coexistent mood disturbance. Because of the different effects of stimulants and antidepressants, some patients may benefit from the combination of a stimulant and an antidepressant.",
"   </p>",
"   <p>",
"    Adverse effects of antidepressants often limit the ability to titrate the dose to an effective level. Drowsiness is common but may be minimized by taking the antidepressant at bedtime and slowly titrating to the target dosage. Anticholinergic effects such as dry mouth, constipation, and urinary retention may be troublesome, as are weight gain and postural hypotension. Sexual dysfunction is more common with the agents that affect serotonin reuptake than with secondary amine TCAs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If sedation is problematic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    may be an alternative agent. The use of bupropion is contraindicated in patients with a history of seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937226\">",
"    <span class=\"h1\">",
"     ATOMOXETINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    (Strattera) is a selective norepinephrine reuptake inhibitor approved by the United States Food and Drug Administration (US FDA) for the treatment of ADHD in children older than 6 years, adolescents, and adults. It is the only FDA approved medication for the treatment of ADHD that is not controlled under the Controlled Substance Act and the first ADHD pharmacotherapy approved for use in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/32\">",
"     32",
"    </a>",
"    ]. A warning was issued by the FDA in 2005 that atomoxetine has been associated with an increased risk of suicide in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    is an oral capsule (5, 10, 18, 25, 40, and 60 mg) and can be taken once or twice per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/32\">",
"     32",
"    </a>",
"    ]. Approval in adults was based on two ten week trials that tested atomoxetine in total daily doses of 60 to 120",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (mean 95",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    in which ADHD symptoms were significantly improved compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/34\">",
"     34",
"    </a>",
"    ]. It is recommended that adults be started at a dose of 40 mg for a minimum of three days, and then increased to 80 mg; the dose may be increased to a maximum of 100 mg after two to four weeks. Alternatively, some recommend starting at 25 mg for one week, increasing to 50 mg for week two and then titrating upwards.",
"   </p>",
"   <p>",
"    Adverse effects include (but are not limited to) weight loss, abdominal pain, decreased appetite, vomiting, nausea, dyspepsia, and sleep disturbance. In addition, based on reports of severe liver injury in two patients (a teenager and an adult) who were being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    for several months, the US FDA added a warning that atomoxetine should be discontinued in patients who develop jaundice or laboratory evidence of liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937233\">",
"    <span class=\"h1\">",
"     METADOXINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metadoxine, a nonstimulant, 5-hydroxytryptamine receptor antagonist, has been found to reduce symptoms of ADHD in adults with the disorder. In a randomized trial, 120 adults with ADHD were treated with metadoxine extended release (ER) or placebo daily for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/36\">",
"     36",
"    </a>",
"    ]. An intention to treat analysis found that metadoxine led to reduced ADHD symptoms compared to placebo. More patients in the metadoxine group experienced a 40 percent reduction in ADHD symptoms compared with those in the placebo group (43 versus 24 percent). The medication was well tolerated. These promising results need further study in additional clinical trials, including comparison to other medications effective for adult ADHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937240\">",
"    <span class=\"h1\">",
"     OTHER MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympatholytics have been used in the management of ADHD.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    is a centrally acting alpha-2 agonist that decreases sympathetic outflow from the CNS. While this agent may be beneficial in children and adolescents, particularly those with significant hyperactivity and aggressive behavior, the benefits in adults are less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/37\">",
"     37",
"    </a>",
"    ]. Sedation is the most common adverse effect of clonidine. The antihypertensive effects of clonidine may be beneficial in a patient with hypertension but may limit its usefulness in other patients.",
"   </p>",
"   <p>",
"    A number of complementary and alternative medicine therapies have been tried in patients with ADHD. The efficacy is uncertain; further research is required before any can be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937247\">",
"    <span class=\"h1\">",
"     MEDICATION SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants are a major component of pharmacologic therapy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The bulk of the data in adults supports the efficacy of stimulants. However, the addicting nature of stimulants, the chronicity of ADHD, and the large number of potentially comorbid conditions in adults have led some experts to recommend a trial of a nonstimulant agent first.",
"   </p>",
"   <p>",
"    Nevertheless, for the patient with no contraindications, long-term stimulant use is a reasonable choice for pharmacologic therapy. The efficacy of all of the stimulants appears to be similar, although the greatest experience is with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    . For the patient with a history of substance abuse, a tricyclic antidepressant (TCA) that has activity through norepinephrine pathways (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    might be a preferred agent. For the patient with cardiac or other medical contraindications to stimulants or TCAs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    is a reasonable alternative.",
"   </p>",
"   <p>",
"    There are limited data comparing the stimulants to antidepressants, but the available research suggests that they are similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/39\">",
"     39",
"    </a>",
"    ]. A reasonable approach is to start with an agent of one class and switch to an agent from another class if the patient fails to respond or has significant side effects. As mentioned, combinations of these drugs can also be used.",
"   </p>",
"   <p>",
"    For patients with mood, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substance abuse conditions who also have features of ADHD, the primary condition should be initially treated and ADHD symptoms addressed if they persist after remission of the primary condition. Conversely, ADHD should be considered when patients fail to respond to pharmacotherapy for a mood or anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102937254\">",
"    <span class=\"h1\">",
"     EFFECTS ON HIGH RISK BEHAVIORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD symptoms are typically chronic, but lack of treatment and discontinuous pharmacotherapy are common. Some but not all studies suggest that treatment of ADHD in childhood or adulthood is associated with lower rates of problem behaviors in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six studies following children with ADHD into adolescence or young adulthood found that children who did not receive medication (stimulant therapy) had twice the risk of subsequent substance abuse compared with those who did receive medication (OR 1.9, 95% CI 1.1-3.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/41\">",
"       41",
"      </a>",
"      ]. Two subsequent prospective studies, in contrast, concluded that stimulant treatment did not impact risk for adult substance abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/42,43\">",
"       42,43",
"      </a>",
"      ] and one found that early rather than later initiation of stimulant therapy in childhood was associated with lower levels of adult substance abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Short-term clinical trials of medication in adults with ADHD have shown a beneficial effect of treatment on conduct problems [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/45,46\">",
"       45,46",
"      </a>",
"      ], but longer-term studies have been limited by high dropout out rates. A study using national registry data on 25,656 Swedish individuals, age 16 years or older and diagnosed with ADHD, compared subjects&rsquo; criminal conviction rates during periods while they were receiving ADHD medication to conviction rates during periods while not receiving medication between 2006 and 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/47\">",
"       47",
"      </a>",
"      ]. Conviction rates decreased 32 and 41 percent in men and women, respectively, during periods receiving medication compared to periods off medication [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20599/abstract/45-47\">",
"       45-47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102938058\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stimulants are the most commonly used medications in adults with ADHD, but response rates may be lower than in children. Stimulants differ in pharmacokinetics but have similar efficacy. Blood pressure and heart rate should be closely monitored when initiating stimulant treatment in adults. Stimulants should be avoided in patients with history of or increased risk for substance abuse.",
"     </li>",
"     <li>",
"      Secondary amine tricyclic antidepressants (TCAs) with activity through norepinephrine pathways (eg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      have been effective as monotherapy for ADHD, or in combination with stimulants. An electrocardiogram should be obtained before initiating TCA therapy, and after achieving target dose.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"       Atomoxetine",
"      </a>",
"      is the only approved medication for the treatment of ADHD that is not controlled under the Controlled Substance Act in the US. There are case reports of severe liver injury, and other adverse effects include gastrointestinal symptoms and sleep disturbance.",
"     </li>",
"     <li>",
"      Adult ADHD is a chronic, life-long condition with onset in childhood; continued pharmacotherapy throughout adulthood is usually indicated. For the patient with no contraindications, long-term stimulant use is a reasonable choice. For the patient with a history of substance abuse, a tricyclic antidepressant or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"       atomoxetine",
"      </a>",
"      is preferred.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      is a reasonable alternative for the patient with cardiac or other medical contraindications to stimulants or TCAs.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/1\">",
"      Vollmer, S. AD/HD: it's not just in children. Family Practice Recertification 1998; 20:45.",
"     </a>",
"    </li>",
"    <li>",
"     Wender, PH. Attention-Deficit Hyperactivity Disorder in Adults, Oxford University Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/3\">",
"      Cantwell DP. Hyperactive children have grown up. What have we learned about what happens to them? Arch Gen Psychiatry 1985; 42:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/4\">",
"      Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/5\">",
"      Okie S. ADHD in adults. N Engl J Med 2006; 354:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/6\">",
"      Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Wilens, TE, Spencer, et al. Phamacotherapy of adult ADHD. In: Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd ed, Barakley, RA (Eds), Guilford, New York 1998. p.592.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/8\">",
"      A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder, Agency for Healthcare Research and Quality, Rockville, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/10\">",
"      Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis 2000; 188:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/11\">",
"      Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/12\">",
"      Lutton ME, Leach L, Triezenberg D. Clinical inquiries. Does stimulant therapy help adult ADHD? J Fam Pract 2003; 52:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/13\">",
"      Schweitzer JB, Cummins TK, Kant CA. Attention-deficit/hyperactivity disorder. Med Clin North Am 2001; 85:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/14\">",
"      Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/15\">",
"      Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/16\">",
"      Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/17\">",
"      Drugs for treatment of ADHD. Treat Guidel Med Lett 2006; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/18\">",
"      Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001; 931:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/19\">",
"      Paterson R, Douglas C, Hallmayer J, et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999; 33:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/20\">",
"      Lisdexamfetamine dimesylate (Vyvanse) for ADHD. Med Lett Drugs Ther 2007; 49:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/21\">",
"      Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/22\">",
"      Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/23\">",
"      Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005; 66:253.",
"     </a>",
"    </li>",
"    <li>",
"     Spencer TJ, Biederman J, Wilen T. of ADHD with antidepressants. In: Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd ed, Barkley RA (Ed), Guilford, New York 1998. p.522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/25\">",
"      Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 1998; 59 Suppl 7:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/26\">",
"      Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21:RC121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/27\">",
"      Vastag B. Pay attention: ritalin acts much like cocaine. JAMA 2001; 286:905.",
"     </a>",
"    </li>",
"    <li>",
"     Manufacturer's prescribing information for lisdexamfetamine. www.vyvanse.com/pdf/prescribing_information.pdf.",
"    </li>",
"    <li>",
"     Spencer, TJ, Biederman, J, Wilen, T. Pharmacotherapy of ADHD with antidepressants. In: Barkley, RA (ed), Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd ed, New York, Guilford, 1998, p. 522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/30\">",
"      Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/31\">",
"      Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005; 57:793.",
"     </a>",
"    </li>",
"    <li>",
"     Strattera, package insert, Eli Lilly and Company, November, 2002.",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2005/safety05.htm#Strattera (Accessed October 5, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/34\">",
"      Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53:112.",
"     </a>",
"    </li>",
"    <li>",
"     New warning for strattera. FDA Talk Paper, December 17, 2004, www.fda.gov/bbs/topics/ANSWERS/2004/ANS01335.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/36\">",
"      Manor I, Ben-Hayun R, Aharon-Peretz J, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012; 73:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/37\">",
"      Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/38\">",
"      Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann N Y Acad Sci 2001; 931:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/39\">",
"      Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract 1999; 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/40\">",
"      Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996; 62:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/41\">",
"      Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/42\">",
"      Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/43\">",
"      Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 2008; 165:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/44\">",
"      Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/45\">",
"      Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/46\">",
"      Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20599/abstract/47\">",
"      Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17158 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20599=[""].join("\n");
var outline_f20_7_20599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H102938058\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102935206\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937177\">",
"      OVERVIEW OF PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937184\">",
"      STIMULANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102937191\">",
"      Stimulant preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102937198\">",
"      Cardiovascular side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102937205\">",
"      Other side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102937212\">",
"      Abuse potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937219\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937226\">",
"      ATOMOXETINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937233\">",
"      METADOXINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937240\">",
"      OTHER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937247\">",
"      MEDICATION SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102937254\">",
"      EFFECTS ON HIGH RISK BEHAVIORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102938058\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/17158\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/17158|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/32/23054\" title=\"table 1\">",
"      Drugs for ADHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20600="Penicillin skin testing";
var content_f20_7_20600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Penicillin skin testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20600/contributors\">",
"     Roland Solensky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20600/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20600/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/7/20600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22605785\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin skin testing is a tool used in the diagnosis of penicillin allergy. This topic will review the indications, safety, protocols, and interpretation of skin testing with penicillin and the aminopenicillins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An overview of allergy skin testing (for various types of allergens), a general discussion of the diagnosis of drug allergy, and the clinical manifestations of penicillin allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link\">",
"     \"An approach to the patient with drug allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22605793\">",
"    <span class=\"h1\">",
"     INFORMATION PROVIDED BY SKIN TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is a bioassay, performed on the skin, which detects the presence of allergen-specific IgE on a patient's mast cells. When allergen is introduced into the skin of a patient during skin testing, it comes into contact with cutaneous mast cells. Binding of the allergen occurs if the patient's mast cells are coated with IgE recognizing that specific allergen. If both IgE and allergen are present in sufficient quantities, then adjacent allergen-specific IgE molecules become cross-linked on the mast cell surface and the cells are activated.",
"   </p>",
"   <p>",
"    Mast cell activation results in a positive skin test, which is a transient \"wheal-and-flare\" reaction within 15 to 20 minutes from application of the allergen. This reaction consists of a central area of superficial skin edema (wheal) surrounded by erythema (flare). This pruritic reaction represents the immediate phase of the allergic reaction. If the patient&rsquo;s cutaneous mast cells are not activated, then no edema or erythema develops and the test is negative. Falsely negative skin tests can result when patients have received medications such as antihistamines that block the skin effects of immediate mast cell mediators. (See",
"    <a class=\"local\" href=\"#H2466840\">",
"     'Patient preparation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with detectable penicillin-specific IgE on their mast cells are said to be &ldquo;sensitized&rdquo; to penicillin and are at high risk for an immediate allergic reaction to the drug. Immediate allergic reactions are defined as those reactions that begin within one hour of administration of a medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H8#H8\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Classification of drug allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most immediate allergic reactions to drugs like penicillin are IgE-mediated, Gell and Coombs type I hypersensitivity reactions (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ). The most severe form of IgE-mediated reaction is anaphylaxis. Skin testing is the best method for detecting patients at risk for penicillin-induced anaphylaxis, in part because it is more sensitive than in vitro tests for penicillin-specific IgE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22604319\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is the most rapid, sensitive, and cost-effective testing modality for evaluating patients with immediate allergic reactions to penicillin and related drugs. Results of skin testing are obtained in less than an hour with minimal patient discomfort.",
"   </p>",
"   <p>",
"    Immediate reactions are defined as those that begin within one hour of administration. Immediate reactions have characteristic signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the results are most likely to be positive in patients with immediate reactions, skin testing is also useful in excluding immediate reactions in patients with unclear histories of past penicillin reactions, such as isolated urticaria or unspecified rash. Skin testing has no role in the diagnosis of exfoliative skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN), or in reactions that are caused by other known mechanisms (eg, hemolytic anemia, interstitial nephritis).",
"   </p>",
"   <p>",
"    Skin testing is ideally performed when the patient is well and not in urgent or immediate need of antibiotic therapy. The indications for penicillin skin testing are evolving, with a trend for testing more patients even if they have alternatives to penicillin or beta-lactam therapy. Penicillin skin testing was traditionally reserved for patients who required penicillins because there was no other suitable antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/1\">",
"     1",
"    </a>",
"    ], a situation that has become increasingly uncommon. However, alternative antibiotics are often less effective, more toxic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more expensive than available penicillins. In addition, it is important to avoid unnecessary use of broad spectrum antibiotics. (See",
"    <a class=\"local\" href=\"#H27039759\">",
"     'Clinical impact'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H668928\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to penicillin skin testing are similar to those for other forms of skin testing, which are mentioned briefly here and discussed in more detail separately: (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of skin testing for allergic disease\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain skin conditions (chronic urticaria, dermatographism) in which the skin is over-reactive and false positive results may occur if not properly controlled for.",
"     </li>",
"     <li>",
"      The inability to temporarily discontinue medications that either interfere with skin test interpretation, or inhibit the clinician&rsquo;s ability to treat anaphylaxis, should it occur as a result of testing (which is rare). (See",
"      <a class=\"local\" href=\"#H2466840\">",
"       'Patient preparation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Severe exfoliative past reactions to penicillin, such as toxic epidermal necrolysis (TEN), in which exposure to even minute amounts of the drug could cause recurrent symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27039759\">",
"    <span class=\"h2\">",
"     Clinical impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;An underappreciated aspect of penicillin allergy is the morbidity, mortality, and economic cost associated with the unnecessary withholding of penicillins in patients who are assumed to be allergic on the basis of history alone. Patients labeled penicillin-allergic are more likely to be treated with broad-spectrum antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and quinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. In one study, hospitalized patients with a history of penicillin allergy were about twice as likely to receive vancomycin (39.7 versus 17.4 percent) and almost three times as likely to receive quinolones (21.5 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The unnecessary use of broad-spectrum agents confers distinct disadvantages. Non-beta-lactam antibiotics may be more expensive, associated with more side effects (such as Clostridium difficile), and in some cases, less efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Additionally, overuse of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and quinolones contributes to the development and spread of certain types of drug-resistant bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. As an example, one study assessed various risk factors for the development of vancomycin resistant enterococcus (VRE) in a medical intensive care unit (MICU) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/14\">",
"     14",
"    </a>",
"    ]. Among pre-MICU treatment with various classes of antibiotics, quinolones had the strongest association with subsequent development of VRE (odds ratio = 8.6), whereas treatment with",
"    <span class=\"nowrap\">",
"     penicillins/beta-lactamase",
"    </span>",
"    inhibitors was not associated with developing VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\", section on 'Risk Factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an effort to improve appropriate utilization of antibiotics, a number of medical centers have instituted penicillin skin testing protocols and demonstrated the impact of proactive testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/15-27\">",
"     15-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the Mayo Clinic, when penicillin skin testing was incorporated into the preoperative evaluation of surgical patients with a history of penicillin allergy, there was a 10-fold decrease in the use of preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (in favor of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/15,23\">",
"       15,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At the Cleveland Clinic, implementation of penicillin skin testing in patients with a history of penicillin allergy resulted in large reductions in the use of quinolones (64 percent),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (55 percent), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (69 percent) in those individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22604326\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin skin testing should be performed only by specifically trained personnel, usually allergy specialists, because any procedure that involves the deliberate exposure of a patient to a substance to which they may be allergic should be undertaken by someone with expertise in that technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669643\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although penicillin skin testing performed in the described manner rarely leads to systemic allergic reactions, testing should take place in a setting prepared to treat possible allergic reactions, including anaphylaxis. Fatal anaphylaxis in response to testing has not been reported since modern skin testing methods have been in use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/15,28-31\">",
"     15,28-31",
"    </a>",
"    ]. Skin testing has been safely performed in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22604333\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin skin testing involves (at least) two steps. Epicutaneous (prick-puncture) skin testing should be performed first, and, if negative, intradermal tests should follow. Epicutaneous testing is performed initially because systemic allergic reactions are possible and are more likely with intradermal testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H6476491#H6476491\">",
"     \"Overview of skin testing for allergic disease\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2466840\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors should be considered when planning penicillin skin testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin testing should not be performed in the weeks immediately following an episode of anaphylaxis, because during this type of severe allergic reaction, there is massive activation of mast cells, and the cells may then be hyporeactive for a period of time. A period of at least four weeks should be allowed to elapse before any skin testing is performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of skin testing for allergic disease\", section on 'Recent anaphylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient&rsquo;s medications should be reviewed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Any medications that could interfere with the results of skin testing (eg, antihistamines) should be temporarily discontinued, if possible. The duration that various medications should be withheld is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of skin testing for allergic disease\", section on 'Medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any medications that could interfere with the ability to treat anaphylaxis should be noted (eg, beta blockers, ACE inhibitors). If possible, these medications may be held temporarily (particularly in patients with extremely severe reaction histories) or this may not be necessary since most patients are very unlikely to develop anaphylaxis as a result of skin testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of skin testing for allergic disease\", section on 'Presence of interfering medications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27040356\">",
"    <span class=\"h2\">",
"     Skin testing reagents and concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most penicillin-allergic patients are not allergic to the intact penicillin molecule. The majority of patients are allergic to degradation products of penicillin covalently linked to self proteins. Thus, skin testing with a simple solution of the drug as it is normally administered is not adequate to identify allergy in most patients. Insight into the immunochemistry of penicillin allowed for the development of skin testing reagents to detect penicillin-specific IgE antibodies (",
"    <a class=\"graphic graphic_figure graphicRef67647 \" href=\"UTD.htm?6/58/7086\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Penicillin skin testing is usually performed with the following reagents (",
"    <a class=\"graphic graphic_table graphicRef58347 \" href=\"UTD.htm?5/34/5675\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major determinant:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"       penicilloyl-polylysine",
"      </a>",
"      (Pre-Pen",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) (6 x 10",
"      <sup>",
"       -5",
"      </sup>",
"      M)",
"     </li>",
"     <li>",
"      The minor determinants:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      (10,000",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Penicilloate (if available) (0.01 M)",
"     </li>",
"     <li>",
"      Penilloate (if available) (0.01 M)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      and or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (3 to 25",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      if relevant to the patient&rsquo;s care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The minimal reagents required are positive and negative controls, the major determinant (PPL) and the minor determinant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    . The minor determinant mixture is included if available, and the aminopenicillins are included if the patient reacted to these drugs or may need them in the future.",
"   </p>",
"   <p>",
"    In the rare patient with a history of exquisite penicillin sensitivity (eg, a nurse who reacts to airborne penicillin), initial skin testing reagents may be diluted beyond the standard concentrations.",
"   </p>",
"   <p>",
"    Penicillin intradermal skin testing involves raising a 2 to 3 mm bleb in the skin with each of the test solutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of skin testing for allergic disease\", section on 'Intradermal method'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each test solution may be applied in duplicate (as stated in the Pre-Pen",
"    <sup>",
"     &reg;",
"    </sup>",
"    package insert) or singly. The recommendation to test in duplicate comes from a single large study in which 7 percent of duplicate tests were discordant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/28\">",
"     28",
"    </a>",
"    ]. If a single intradermal test result is equivocal, it should be repeated in duplicate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669689\">",
"    <span class=\"h3\">",
"     Controls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both a positive control of histamine (10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    as histamine dichloride; 6.6",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    as histamine base, for epicutaneous use) and a negative intradermal control of diluent identical to that of the allergen extracts (usually glycerinated saline) should always be applied in order to verify that the patient's skin is normally responsive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22605965\">",
"    <span class=\"h3\">",
"     Major determinant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of penicillin antigens arise from degradation to the penicilloyl determinant following administration, as discussed previously. Penicilloyl is the major determinant, and when complexed to polylysine, it constitutes a multivalent skin test reagent known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"     penicilloyl-polylysine",
"    </a>",
"    (PPL). PPL is critical for reliable skin testing, as up to 75 percent of penicillin skin test-positive patients react only to PPL, depending on the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/28,32,33\">",
"     28,32,33",
"    </a>",
"    ]. Hence, skin testing without PPL may fail to identify many penicillin-allergic individuals and is not recommended.",
"   </p>",
"   <p>",
"    PPL is commercially available as Pre Pen",
"    <sup>",
"     &reg;",
"    </sup>",
"    . This product was not available in the United States for several years, but its production was resumed in late 2009. Other products may be available in different countries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/34\">",
"     34",
"    </a>",
"    ]. Pre Pen",
"    <sup>",
"     &reg;",
"    </sup>",
"    contains PPL at a single concentration of 6 x 10",
"    <sup>",
"     -5",
"    </sup>",
"    molar penicilloyl, and is applied to the skin undiluted for both prick and intradermal testing. Diluted solutions may be used initially for the rare patient whose history suggests exquisite sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22605972\">",
"    <span class=\"h3\">",
"     Minor determinants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minor penicillin antigenic determinants are benzylpenicillin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ), benzylpenicilloate, and benzylpenilloate. Of these, only penicillin G is currently available commercially.",
"   </p>",
"   <p>",
"    Standard intravenous preparations of benzylpenicillin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ) may be used for skin testing at a concentration of 10,000",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58347 \" href=\"UTD.htm?5/34/5675\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Benzylpenicilloate and benzylpenilloate (also known as minor determinant mixture, or MDM) are not commercially available (except for a product for use in Spain and South America), but the importance of these reagents is controversial. In large-scale studies, about 10 percent of penicillin skin test-positive patients are positive only to penicilloate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    penilloate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/28,32-39\">",
"     28,32-39",
"    </a>",
"    ]. One small study suggested that patients who tested positive only to the MDMs were at higher risk for severe allergic reactions. However, larger studies found that the negative predictive value of skin testing with PPL + MDM was similar to that of PPL + benzylpenicillin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/18,29,40,41\">",
"     18,29,40,41",
"    </a>",
"    ]. Stated differently, although patients exist who only test positive to MDM, challenges of patients skin test-negative to PPL and benzylpenicillin had similar reaction rates compared to patients skin test-negative to the full set of major and minor penicillin determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/28,36,42\">",
"     28,36,42",
"    </a>",
"    ]. However, these studies had insufficient power to detect a small difference in rates. Thus, the presumed clinical value of the MDM as a skin testing reagent compared with benzylpenicillin alone is based on the observation that a few more patients with positive skin tests will be detected using the full skin test battery (",
"    <a class=\"graphic graphic_table graphicRef58347 \" href=\"UTD.htm?5/34/5675\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22605979\">",
"    <span class=\"h3\">",
"     Aminopenicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminopenicillins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , should be included in the skin testing panel for any patient who reports an immediate systemic reaction to these drugs. Patients who are selectively allergic to the aminopenicillins form IgE antibodies which recognize, at least in part, the side R-group side chain rather than the core penicilloyl determinant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. These individuals react only to amoxicillin or ampicillin on skin testing, and are negative to PPL, benzylpenicillin, and MDM. The importance of the MDM in diagnosing selective allergy to the aminopenicillins is not clear, for the reasons discussed previously.",
"   </p>",
"   <p>",
"    Concentrations ranging from 3 to 25",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of aminopenicillins have been reported to be nonirritating and may be used for skin testing (",
"    <a class=\"graphic graphic_table graphicRef58347 \" href=\"UTD.htm?5/34/5675\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/32,44,47-49\">",
"     32,44,47-49",
"    </a>",
"    ]. In our clinic, we use the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      : 3",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (prepared via a compounding pharmacy from bulk amoxicillin available as sodium salt of the pure acid) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Europe, higher concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      have been used, and these require that the sodium salt is used and also require a higher pH in order to maintain solubility [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      : 2.5",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      which may be prepared as a 10-fold dilution from commercially available IV ampicillin (25",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667452\">",
"    <span class=\"h3\">",
"     Clavulanate testing in patient reactive to amoxicillin/clavulanate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who reacted to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    may be allergic to clavulanate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Clavulanate allergy should be considered in a patient who reacted to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate, but has negative skin tests to penicillin and amoxicillin reagents. Although skin testing to clavulanate alone (20",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    is more sensitive than testing with the combination of amoxicillin and clavulanate, obtaining clavulanate for testing is extremely difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22604340\">",
"    <span class=\"h2\">",
"     Interpretation of results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prick-puncture skin testing results are read 15 minutes after application:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive response is a wheal that is 3 mm or greater in mean diameter than the negative control.",
"     </li>",
"     <li>",
"      A negative response is no reaction at the prick site or erythema alone without a wheal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intradermal skin testing is read 15 to 20 minutes after application:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive response is a wheal that has increased in size from the original bleb and is 3 mm or greater in mean diameter than the negative control.",
"     </li>",
"     <li>",
"      A negative response is no increase in the size of the original bleb and no wheal greater than the control site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22604347\">",
"    <span class=\"h3\">",
"     Positive predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the positive predictive value of penicillin skin testing are limited due to ethical concerns of challenging skin test-positive patients with penicillin. In addition, drug-specific IgE is believed to be a necessary but not always sufficient factor for a symptomatic drug reaction. The available data suggest that approximately 50 percent (range 33 to 100 percent) of penicillin skin test-positive patients develop immediate allergic reactions upon being challenged with penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/29,36,37,42,54-57\">",
"     29,36,37,42,54-57",
"    </a>",
"    ]. This rate is comparable to that observed in hymenoptera allergy skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who test positive to penicillin should avoid all penicillins (ie, including the aminopenicillins and newer semisynthetic penicillins). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969463#H1969463\">",
"     \"Allergy to penicillins\", section on 'Options for future treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22604354\">",
"    <span class=\"h3\">",
"     Negative predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative predictive value of penicillin skin testing is very high. Serious immediate reactions in patients challenged with penicillin following negative penicillin skin testing have not been reported. In large-scale studies, 1 to 3 percent of penicillin skin test-negative patients developed mild, usually self-limiting reactions upon being challenged with the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/18,28,31,36,54,59-61\">",
"     18,28,31,36,54,59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned previously, the clinical importance of including the minor determinant mixture (MDM) in skin testing is controversial, since the negative predictive value of skin testing with only PPL and benzylpenicillin is comparable to testing with all the reagents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/18,28,29,36,40-42\">",
"     18,28,29,36,40-42",
"    </a>",
"    ]. The best available estimate is that at least another 10 percent of penicillin-sensitized patients can be discovered by use of the full MDM reagent (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    , benzylpenicilloate, and benzylpenilloate).",
"   </p>",
"   <p>",
"    Skin testing with the aminopenicillins is not as well studied, and very few data are available on the predictive value. There is an impression from the Spanish experience that the negative predictive value is not as high as that of the benzylpenicillin determinants, but this has not been demonstrated conclusively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2468787\">",
"    <span class=\"h2\">",
"     Confirmatory challenge after negative skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with negative skin test results, the absence of allergy should be confirmed by administering an age-appropriate dose of the penicillin to which the patient initially reacted, followed by one to two hours of observation to ensure that an immediate reaction does not occur. Challenge is indicated because the negative predictive value for penicillin skin testing with the combination of PPL and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    is high, but not 100 percent. Also, confirming that the drug is tolerated will maximize the comfort of the patient and other clinicians with using penicillins in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20600/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is best to challenge the patient with the specific penicillin to which they reacted, when possible. The following examples are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient who reacted to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , challenging with amoxicillin ensures that the patient is not selectively allergic to amoxicillin. As discussed previously, the negative predictive value of penicillin skin testing in patients primarily allergic to aminopenicillins is not well defined. Challenge with amoxicillin will detect allergy to amoxicillin or penicillin, whereas challenge with penicillin would only identify penicillin allergy.",
"     </li>",
"     <li>",
"      In a patient who reacted to",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"        amoxicillin",
"       </a>",
"       /clavulanate,",
"      </span>",
"      challenge with the combination can help identify clavulanate allergy, if both penicillin and amoxicillin skin tests were negative but clavulanate was not available for testing.",
"     </li>",
"     <li>",
"      For testing of inpatients with a current need for a particular penicillin product, the challenge procedure can be incorporated into the first parenteral dose by administering one-tenth of a normal dose, observing for one hour, then if there is no adverse reaction, administering the remaining nine-tenths of the dose and observing for another hour. Patients who tolerate this type of challenge prove that they are not allergic and can receive additional doses normally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22605986\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen skin testing is a bioassay that detects the presence of allergen-specific IgE on a patient's mast cells. Patients with detectable penicillin-specific IgE on their mast cells are said to be &ldquo;sensitized&rdquo; to penicillin and are at high risk for an immediate allergic reaction to the drug. Skin testing is the most rapid, sensitive, and cost-effective testing modality for identifying penicillin-sensitized patients. (See",
"      <a class=\"local\" href=\"#H22605793\">",
"       'Information provided by skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systematically skin testing patients who have a history of penicillin allergy reveals that most patients are not actually allergic or have lost the allergy over time. Reintroducing penicillin as a treatment option can decrease antibiotic costs, optimize antibiotic choices, and reduce patient complications associated with broad-spectrum antibiotics, such as infections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant enterococcus and Clostridium difficile. (See",
"      <a class=\"local\" href=\"#H27039759\">",
"       'Clinical impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penicillin skin testing is considered a safe procedure, although it should be performed by allergy experts when possible, since they have the training to interpret the results accurately and the experience, staff, and equipment to treat possible (albeit rare) allergic reactions. (See",
"      <a class=\"local\" href=\"#H22604326\">",
"       'Referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H669643\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epicutaneous (prick-puncture) skin testing should be performed first, and if negative, intradermal tests should follow. The minimal reagents required are positive and negative controls, the major determinant (PPL) and the minor determinant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef58347 \" href=\"UTD.htm?5/34/5675\">",
"       table 3",
"      </a>",
"      ). The minor determinant mixture is included if available, and the aminopenicillins are included if the patient reacted to these drugs or may need them in the future. (See",
"      <a class=\"local\" href=\"#H22604333\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The positive predictive value of penicillin skin testing is approximately 50 percent, which is similar to that of skin testing with many other allergens. The negative predictive value is very high (ie, 97 to 99 percent) although it may be lower for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H22604340\">",
"       'Interpretation of results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following negative skin test results, the absence of allergy should be confirmed with a challenge (usually oral). A dose of the penicillin to which the patient reacted in the past is administered and the patient is observed for one to two hours to ensure that an immediate reaction does not occur. (See",
"      <a class=\"local\" href=\"#H2468787\">",
"       'Confirmatory challenge after negative skin testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/1\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/2\">",
"      Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/3\">",
"      Solensky R, Earl HS, Gruchalla RS. Clinical approach to penicillin-allergic patients: a survey. Ann Allergy Asthma Immunol 2000; 84:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/4\">",
"      Puchner TC Jr, Zacharisen MC. A survey of antibiotic prescribing and knowledge of penicillin allergy. Ann Allergy Asthma Immunol 2002; 88:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/5\">",
"      Kwan T, Lin F, Ngai B, Loeb M. Vancomycin use in 2 Ontario tertiary care hospitals: a survey. Clin Invest Med 1999; 22:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/6\">",
"      Cieslak PR, Strausbaugh LJ, Fleming DW, Ling JM. Vancomycin in Oregon: who's using it and why. Infect Control Hosp Epidemiol 1999; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/7\">",
"      MacLaughlin EJ, Saseen JJ, Malone DC. Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy. Arch Fam Med 2000; 9:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/8\">",
"      Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol 2006; 98:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/9\">",
"      Kraemer MJ, Caprye-Boos H, Berman HS. Increased use of medical services and antibiotics by children who claim a prior penicillin sensitivity. West J Med 1987; 146:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/10\">",
"      Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/11\">",
"      Bonafede M, Rice LB. Emerging antibiotic resistance. J Lab Clin Med 1997; 130:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/12\">",
"      Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/13\">",
"      Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998; 55:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/14\">",
"      Mart&iacute;nez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/15\">",
"      Park M, Markus P, Matesic D, Li JT. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 2006; 97:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/16\">",
"      Macy E. Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes. J Allergy Clin Immunol 1998; 102:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/17\">",
"      Macy E. Penicillin skin testing in pregnant women with a history of penicillin allergy and group B streptococcus colonization. Ann Allergy Asthma Immunol 2006; 97:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/18\">",
"      del Real GA, Rose ME, Ramirez-Atamoros MT, et al. Penicillin skin testing in patients with a history of beta-lactam allergy. Ann Allergy Asthma Immunol 2007; 98:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/19\">",
"      Philipson EH, Lang DM, Gordon SJ, et al. Management of group B Streptococcus in pregnant women with penicillin allergy. J Reprod Med 2007; 52:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/20\">",
"      Wall GC, Peters L, Leaders CB, Wille JA. Pharmacist-managed service providing penicillin allergy skin tests. Am J Health Syst Pharm 2004; 61:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/21\">",
"      Nadarajah K, Green GR, Naglak M. Clinical outcomes of penicillin skin testing. Ann Allergy Asthma Immunol 2005; 95:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/22\">",
"      Forrest DM, Schellenberg RR, Thien VV, et al. Introduction of a practice guideline for penicillin skin testing improves the appropriateness of antibiotic therapy. Clin Infect Dis 2001; 32:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/23\">",
"      Li JT, Markus PJ, Osmon DR, et al. Reduction of vancomycin use in orthopedic patients with a history of antibiotic allergy. Mayo Clin Proc 2000; 75:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/24\">",
"      Arroliga ME, Radojicic C, Gordon SM, et al. A prospective observational study of the effect of penicillin skin testing on antibiotic use in the intensive care unit. Infect Control Hosp Epidemiol 2003; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/25\">",
"      Arroliga ME, Wagner W, Bobek MB, et al. A pilot study of penicillin skin testing in patients with a history of penicillin allergy admitted to a medical ICU. Chest 2000; 118:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/26\">",
"      Harris AD, Sauberman L, Kabbash L, et al. Penicillin skin testing: a way to optimize antibiotic utilization. Am J Med 1999; 107:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/27\">",
"      Perencevich EN, Weller PF, Samore MH, Harris AD. Benefits of negative penicillin skin test results persist during subsequent hospital admissions. Clin Infect Dis 2001; 32:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/28\">",
"      Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993; 270:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/29\">",
"      Green GR, Rosenblum AH, Sweet LC. Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G. A cooperative prospective study of the penicillin study group of the American Academy of Allergy. J Allergy Clin Immunol 1977; 60:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/30\">",
"      Valyasevi MA, Van Dellen RG. Frequency of systematic reactions to penicillin skin tests. Ann Allergy Asthma Immunol 2000; 85:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/31\">",
"      Sullivan TJ, Wedner HJ, Shatz GS, et al. Skin testing to detect penicillin allergy. J Allergy Clin Immunol 1981; 68:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/32\">",
"      Macy E, Richter PK, Falkoff R, Zeiger R. Skin testing with penicilloate and penilloate prepared by an improved method: amoxicillin oral challenge in patients with negative skin test responses to penicillin reagents. J Allergy Clin Immunol 1997; 100:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/33\">",
"      Bousquet PJ, Co-Minh HB, Arnoux B, et al. Importance of mixture of minor determinants and benzylpenicilloyl poly-L-lysine skin testing in the diagnosis of beta-lactam allergy. J Allergy Clin Immunol 2005; 115:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/34\">",
"      Matheu V, P&eacute;rez E, Gonz&aacute;lez R, et al. Assessment of a new brand of determinants for skin testing in a large group of patients with suspected beta-lactam allergy. J Investig Allergol Clin Immunol 2007; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     Adkinson NF, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/36\">",
"      Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992; 152:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/37\">",
"      Macy E, Burchette RJ. Oral antibiotic adverse reactions after penicillin skin testing: multi-year follow-up. Allergy 2002; 57:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/38\">",
"      Jost BC, Wedner HJ, Bloomberg GR. Elective penicillin skin testing in a pediatric outpatient setting. Ann Allergy Asthma Immunol 2006; 97:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/39\">",
"      Park MA, Matesic D, Markus PJ, Li JT. Female sex as a risk factor for penicillin allergy. Ann Allergy Asthma Immunol 2007; 99:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/40\">",
"      BROWN BC, PRICE EV, MOORE MB Jr. PENICILLOYL-POLYLYSINE AS AN INTRADERMAL TEST OF PENICILLIN SENSITIVITY. JAMA 1964; 189:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/41\">",
"      Shepherd G. Clinical experience using only PrePen and penicillin G to detect penicillin allergy in hospitalized patients. J Allergy Clin Immunol 1997; 99:S134 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/42\">",
"      Solley GO, Gleich GJ, Van Dellen RG. Penicillin allergy: clinical experience with a battery of skin-test reagents. J Allergy Clin Immunol 1982; 69:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/43\">",
"      Moss RB. Drug allergy in cystic fibrosis. Clin Rev Allergy 1991; 9:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/44\">",
"      Blanca M, Vega JM, Garcia J, et al. Allergy to penicillin with good tolerance to other penicillins; study of the incidence in subjects allergic to beta-lactams. Clin Exp Allergy 1990; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/45\">",
"      Vega JM, Blanca M, Garc&iacute;a JJ, et al. Immediate allergic reactions to amoxicillin. Allergy 1994; 49:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/46\">",
"      Blanca M, Perez E, Garcia J, et al. Anaphylaxis to amoxycillin but good tolerance for benzyl penicillin. In vivo and in vitro studies of specific IgE antibodies. Allergy 1988; 43:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/47\">",
"      Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol 1996; 98:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/48\">",
"      Marcos Bravo C, Luna Ortiz I, Gonz&aacute;lez V&aacute;zquez R. Hypersensitivity to cefuroxime with good tolerance to other betalactams. Allergy 1995; 50:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/49\">",
"      Sastre J, Quijano LD, Novalbos A, et al. Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Allergy 1996; 51:383.",
"     </a>",
"    </li>",
"    <li>",
"     Amoxicillin is available from Sigma-Aldrich, St Louis, MO (product number A 8523). This preparation is not intended for human administration, and use in skin testing may require IRB approval at some centers. www.sigmaldrich.com (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/51\">",
"      Monta&ntilde;ez MI, Torres MJ, Perez-Inestrosa E, Blanca M. Clarification concerning amoxicillin skin testing. J Allergy Clin Immunol 2011; 128:685; author reply 686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/52\">",
"      Fernandez-Rivas M, Perez Carral C, Cuevas M, et al. Selective allergic reactions to clavulanic acid. J Allergy Clin Immunol 1995; 95:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/53\">",
"      Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010; 125:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/54\">",
"      Caubet JC, Kaiser L, Lema&icirc;tre B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/55\">",
"      Adkinson NF Jr, Thompson WL, Maddrey WC, Lichtenstein LM. Routine use of penicillin skin testing on an inpatient service. N Engl J Med 1971; 285:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/56\">",
"      Chandra RK, Joglekar SA, Tomas E. Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child 1980; 55:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/57\">",
"      Levine BB, Zolov DM. Prediction of penicillin allergy by immunological tests. J Allergy 1969; 43:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/58\">",
"      Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/59\">",
"      Mendelson LM, Ressler C, Rosen JP, Selcow JE. Routine elective penicillin allergy skin testing in children and adolescents: study of sensitization. J Allergy Clin Immunol 1984; 73:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/60\">",
"      Kamboj S, Yousef E, McGeady S, Hossain J. The prevalence of antibiotic skin test reactivity in a pediatric population. Allergy Asthma Proc 2011; 32:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/61\">",
"      Macy E, Mangat R, Burchette RJ. Penicillin skin testing in advance of need: multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins. J Allergy Clin Immunol 2003; 111:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20600/abstract/62\">",
"      Warrington RJ, Burton R, Tsai E. The value of routine penicillin allergy skin testing in an outpatient population. Allergy Asthma Proc 2003; 24:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16503 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20600=[""].join("\n");
var outline_f20_7_20600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22605986\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22605785\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22605793\">",
"      INFORMATION PROVIDED BY SKIN TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22604319\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H668928\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27039759\">",
"      Clinical impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22604326\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H669643\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22604333\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2466840\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27040356\">",
"      Skin testing reagents and concentrations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H669689\">",
"      - Controls",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22605965\">",
"      - Major determinant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22605972\">",
"      - Minor determinants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22605979\">",
"      - Aminopenicillins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H667452\">",
"      - Clavulanate testing in patient reactive to amoxicillin/clavulanate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22604340\">",
"      Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22604347\">",
"      - Positive predictive value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22604354\">",
"      - Negative predictive value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2468787\">",
"      Confirmatory challenge after negative skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22605986\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/16503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16503|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/58/7086\" title=\"figure 1\">",
"      PCN major minor det",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 1\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5675\" title=\"table 3\">",
"      PCN skin test reagents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20601="Evaluation and management of adult sexual assault victims";
var content_f20_7_20601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of adult sexual assault victims",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20601/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20601/contributors\">",
"     Carol K Bates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20601/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20601/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/7/20601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual assault is defined as any sexual act performed by one person on another without consent. It may result from the use of force, the threat of force, or from the victim's inability to give consent. Sexual assault victims do not \"entice\" their assailants; sexual assault is an act of conquest and control.",
"   </p>",
"   <p>",
"    The evaluation and treatment of sexual assault are discussed here. Trauma evaluation and sexually transmitted diseases are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95143399\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifetime prevalence of sexual assault in the United States is estimated to be 18 percent in women and 3 percent in men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/1\">",
"     1",
"    </a>",
"    ]. In a national phone survey of college women, 2.8 percent reported completed or attempted sexual assault in a year; the estimated cumulative rate in four years may be as high as one in four [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/2\">",
"     2",
"    </a>",
"    ]. In one series, almost 30 percent of undergraduate women reported a drug-related assault, with alcohol the most common substance involved [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/3\">",
"     3",
"    </a>",
"    ]. About 50 percent of sexual assault victims have some acquaintance with their attackers. Two-thirds of assaulted women over 55 are assaulted in their own home or in a care facility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/4\">",
"     4",
"    </a>",
"    ]. In men, the prevalence of assault appears to be higher among those who are gay, bisexual, veterans, prison inmates, or seeking mental health services [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statistics from the United States federal government only include assaults upon women in the category of \"forcible rape,\" which excludes statutory rape and male victims. Reports of sexual assault using this definition have generally declined annually since 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/6\">",
"     6",
"    </a>",
"    ]. Reported sexual assaults, however, probably represent only a fraction of those committed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/7\">",
"     7",
"    </a>",
"    ]. Only 10 to 15 percent of all sexual assaults will be reported to police and women who know their assailant are less likely to report the assault [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2401136\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of screening for domestic violence, including sexual assault, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2401080\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of sexual assault victims includes several domains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment and treatment of physical injury with special focus on the genitalia",
"     </li>",
"     <li>",
"      Psychological assessment and support",
"     </li>",
"     <li>",
"      Pregnancy assessment and prevention",
"     </li>",
"     <li>",
"      Evaluation, treatment, and prevention of sexually transmitted disease",
"     </li>",
"     <li>",
"      Forensic evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When possible, acute evaluation should be done by providers specifically trained to care for victims of sexual assault. Others may do the evaluation in one of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trained provider is not available.",
"     </li>",
"     <li>",
"      The patient prefers that the examination be done by another provider and cannot be dissuaded, understanding that flawed evaluation may affect the likelihood of identification and prosecution of the perpetrator. Bias will be presumed if the provider is friend or personal physician to victim.",
"     </li>",
"     <li>",
"      The evaluation is occurring later than the locally determined interval for formal evidence collection, which varies from three to seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete evaluations are time intensive and may require three to six hours. Proper evaluation requires maintenance of the chain of custody and evidentiary material. Providers may be asked to testify in court if cases are prosecuted. Patients must be counseled about each component of evaluation and documentation. They may choose to decline some portions after education on the rationale for the procedure and the impact of their choices on health and prosecution outcomes.",
"   </p>",
"   <p>",
"    Requirements for the forensic evaluation will vary by jurisdiction, and it is important for the provider performing the evaluation to know local requirements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Trained providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many institutions in the United States (US) have established SANE (Sexual Assault Nurse Evaluation) models or related programs for acute care [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These trained providers can:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expedite evaluation",
"     </li>",
"     <li>",
"      Improve the consistency and quality of collected forensic evidence and ensure adherence to specific protocols regarding evidence collection and maintenance of the legal \"chain of evidence\".",
"     </li>",
"     <li>",
"      Coordinate state crime lab testing, if appropriate, including assessment for \"date rape\" drugs (Rohypnol, and gamma-hydroxy butyrate, GHB) when appropriate.",
"     </li>",
"     <li>",
"      Increase success of criminal prosecution and provide a bridge between the medical and criminal justice systems",
"     </li>",
"     <li>",
"      Link the victim with community services including Rape Crisis Centers.",
"     </li>",
"     <li>",
"      Improve sensitivity to the psychological trauma experienced by sexual assault victims.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SANE programs are supported at the federal level in the US by the Department of Justice, Office of Victims of Crime. State specific information is available at",
"    <a class=\"external\" href=\"file://www.sane-sart.com/\">",
"     www.sane-sart.com",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should focus upon precise details of the sexual assault for forensic purposes in the event of sexual assault prosecution. Details will also guide the trauma assessment and will help to assess the risk of pregnancy and sexually transmitted disease.",
"   </p>",
"   <p>",
"    Histories must be obtained in a sensitive and supportive manner. Advocates can support patients and help them articulate their needs and questions during the history but advocates should not respond to questions. Family members or other patient supports should be counseled that they might be subpoenaed as witnesses if present and that they should remain passive and silent for the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following details of the history should be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circumstances of the assault, including date, time, location, use of weapons, force, restraints, or threats",
"     </li>",
"     <li>",
"      Whether or not the victim experienced loss of consciousness or memory loss",
"     </li>",
"     <li>",
"      The assailant's physical description along with the assailant's use of drugs or alcohol",
"     </li>",
"     <li>",
"      Specifics regarding oral, vaginal, or anorectal contact or penetration along with presence or absence of ejaculation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      condom use",
"     </li>",
"     <li>",
"      Areas of trauma should be ascertained focusing especially upon the victim's mouth, breasts, vagina, and rectum",
"     </li>",
"     <li>",
"      Bleeding on the part of either assailant or victim may be relevant in assessing the risk of hepatitis or HIV transmission. The source of genital bleeding must be ascertained as it can be life threatening",
"     </li>",
"     <li>",
"      Recent consensual sexual activity before or after the assault including details about site of contact (oral, genital, anorectal) and condom use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Victims should be asked if they have wiped, showered or bathed, changed clothing, eaten, used toothpaste or mouthwash, used enemas, changed or removed a tampon, sanitary pad, or barrier contraceptive device since the assault. Such activities can lower the yield of forensic specimen collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Note that some states require specific forms for documenting the history and examination.",
"   </p>",
"   <p>",
"    The patient should undress for the examination with a sheet beneath her to capture any falling debris for medical evidence. The physical examination should describe the patient's emotional state. The examiner should document any evidence of trauma. If possible, photographs of injuries should be taken with the patient's consent. A ruler or an easily identified object is helpful for indicating the size of objects in photographs. Physical examination evidence of trauma is more likely to be present with examination within 72 hours or assault, and when assaults occurred out of doors or were perpetrated by strangers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extragenital trauma may be more common than anogenital trauma (70.4 versus 26.8 percent) with bruises, abrasions, or erythema on the thigh, upper arm, face or neck particularly common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/14\">",
"     14",
"    </a>",
"    ]. In women, the breasts, external genitalia, vagina, anus, and rectum should be carefully examined. Common sites of genital injury include the posterior fourchette and the labia minora. Genital trauma occurs more commonly in postmenopausal women and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. Detectable trauma is more likely in women reporting vaginal or anal penetration and in virgins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colposcopic examination can enhance detection of areas of milder genital trauma and is now performed by most SANE programs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A Wood's lamp or other UV light source may help identify foreign debris and semen on the skin. Evidence of anogenital trauma is enhanced with colposcopy or use of toluidine blue dye (TBD). However, toluidine dye can be difficult to use and is not endorsed in all US jurisdictions.",
"   </p>",
"   <p>",
"    In male victims, close attention should be paid to the penis and scrotum, evaluating for erythema, ecchymosis, excoriation, laceration, or suction marks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/19\">",
"     19",
"    </a>",
"    ]. Penile examination should focus particularly on the glans and frenulum, and should also assess for urethral discharge. Rectal examination should be considered, and performed if there was anal penetration. The prostate should be assessed for tenderness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Forensic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forensic evaluation should be offered to victims of abuse, but is not mandatory and requires informed consent. If sexual assault is suspected but the patient is unable to provide consent, it is controversial as to whether or not to perform this examination. A previously identified guardian would be authorized to provide consent. In the absence of a guardian or surrogate decision maker, portions of the examination might be done if routine examination already requires examination of those areas, would not induce additional discomfort,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if a medical procedure is to be done that would destroy evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Components of examination should",
"    <strong>",
"     not",
"    </strong>",
"    be done if they would require sedation, and photographs of intimate areas should not be taken without consent. Materials obtained prior to consent would only be released to law enforcement when consent is obtained later.",
"   </p>",
"   <p>",
"    Forensic evaluation requires collection of numerous specimens. If the patient is brought by ambulance from the site of the assault, any sheets used to transport the patient and any debris on them should be kept [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/9\">",
"     9",
"    </a>",
"    ]. Providers should use evidence collection kits with careful attention to guidelines for specimen collection. There are a variety of commercial collection kits available; some states require specific kits. Kits can be obtained through state distribution programs or directly from kit manufacturers (for example, www.tritechusa.com, www.sirchie.com, www.lynnpeavey.com). States in the United States are required to offer free evidence collection, irrespective of a victim's intent to pursue police reporting, in order to qualify for federal funds in the STOP program [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Collected samples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The victim's clothing",
"     </li>",
"     <li>",
"      Swabs and smears from the buccal mucosa, vagina, and rectum and from other areas highlighted by ultraviolet light",
"     </li>",
"     <li>",
"      Combed specimens from the scalp and pubic hair",
"     </li>",
"     <li>",
"      Fingernail scrapings and clippings",
"     </li>",
"     <li>",
"      Control samples of the victim's scalp and pubic hair (ideally, at least 20 to 25 pulled hairs per site)",
"     </li>",
"     <li>",
"      Whole blood sample",
"     </li>",
"     <li>",
"      Saliva sample",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the painful and invasive nature of plucking hairs and the fact that hair can be removed from a victim at a later date as long as the victim is available, some jurisdictions no longer require hair samples. It is best to check with the local prosecutor&rsquo;s office to clarify their policy. Kits contain specific collection materials, specific containers for each specimen obtained, and detailed collection instructions. Specimens may need to be dried; some jurisdictions mandate specific drying techniques. When completed, kits must be sealed, labeled, and stored using kit-specific directions to ensure rigor in maintaining an unbroken chain of evidence.",
"   </p>",
"   <p>",
"    Samples are examined for spermatozoa and for acid phosphatase as an assay for semen; it is recommended that these analyses be performed in forensic laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/22\">",
"     22",
"    </a>",
"    ]. Collected samples can also be analyzed for DNA. Sperm has been detected in vaginal samples up to 72 hours after assault and in anal samples up to 24 hours after assault; sperm are not generally detectable in oral samples [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The yield of evidentiary exams generally declines with time and with specific behaviors like changing clothes, showering, and brushing teeth. However, there is no absolute interval during which evidence must be obtained, and as DNA technologies develop the time available for evidence collection may expand [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/12\">",
"     12",
"    </a>",
"    ]. The key principle is that there is only one opportunity to collect evidence so when in doubt it is best to obtain it. Individual jurisdictions determine the maximal time interval during which certain evidence may be collected; intervals vary depending upon patient history, hygiene, and the specimen being obtained. As an example, swabs from external skin would not be useful in a victim who presents over 24 hours after an assault and has showered in the interim, but cervical and vaginal swabs, and possibly fingernail scrapings, would still be valuable. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Perpetrator evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians may occasionally be called upon to perform forensic evaluation of an assault perpetrator [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/23\">",
"     23",
"    </a>",
"    ]. Principles for evidentiary examinations are similar to those for victims, and require evidence collection kits and strict attention to maintain the chain of evidence. Because the suspect has the right to remain silent, no history may be given but if the examiner inquires and the suspect responds then all historical information should be recorded. Swabs, hair combing, and fingernail sampling are obtained. Penile swabs should be collected from the shaft, glans, and area under the foreskin; finger swabs would be done in cases of digital penetration of a victim [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/19\">",
"     19",
"    </a>",
"    ]. Bruises, scratches and bite marks are identified, with swabbing of bites and scratches to identify victim DNA. Blood samples for HIV and hepatitis B can be drawn and held; in many jurisdictions victims can ask the court to have the suspect tested.",
"   </p>",
"   <p>",
"    Physical examination evidence of trauma is most common on the hands, forearms, face, and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/14\">",
"     14",
"    </a>",
"    ]. Permanent physical attributes, such as tattoos, are described. If victim and assailant are in the same facility, they should be evaluated in physically separate settings by different personnel to avoid any accusation of cross contamination of specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is focused on trauma assessment, testing for sexually transmitted diseases (STD), and pregnancy testing. Radiographic imaging will be guided by the history and physical.",
"   </p>",
"   <p>",
"    Testing for sexually transmitted infection is generally not done because it is expensive, does not provide any evidentiary material, and requires follow-up appointments. Historically, there has been concern that positive tests might be used by the defense as discrediting evidence of promiscuity, though all US states now limit the evidentiary use of a victim&rsquo;s prior sexual history [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/24\">",
"     24",
"    </a>",
"    ]. However, although it rarely occurs, evidence of an STD obtained at the time of the evaluation for assault could be accessed later, and some patients or providers may choose to defer testing for this reason. The examiner should not perform or delete tests or questions based upon the possible effect on the victim&rsquo;s case; this is considered advocacy and the examiner must remain objective.",
"   </p>",
"   <p>",
"    Testing may be forgone if patients plan to take prophylactic treatment for infections. Testing is more important in the patient who initially declines treatment to ensure that appropriate therapy can occur.",
"   </p>",
"   <p>",
"    2010 guidelines from the United States Centers for Disease Control suggest the following initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tests for chlamydia and gonorrhea using nucleic acid amplification testing (NAAT).",
"     </li>",
"     <li>",
"      Wet mount and culture or point-of-care testing of a vaginal swab for trichomonas. The wet mount can also be examined for evidence of bacterial vaginosis and candidiasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum testing for HIV infection, hepatitis, and syphilis should be considered on an individual basis. Baseline HIV test counseling should occur with options of confidential and anonymous testing offered and explained [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any sites of contact (vagina, rectum, pharynx, mouth) can be sampled for gonorrhea and chlamydia. Wet preps may also show motile sperm; jurisdictions vary as to whether the examiner or the forensic laboratory is to make that evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancy testing should be done for women of childbearing age. Baseline tests for HIV, syphilis and hepatitis B should be done on an individualized basis, with options of confidential and anonymous HIV testing offered and explained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug screening for flunitrazepam (Rohypnol, the \"date rape drug\"), gamma-hydroxy butyrate (GHB) and other drugs should be done selectively if the victim has amnesia for any time surrounding the event. Alcohol may be the most common date rape drug; benzodiazepines and other sedatives may also be implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/14\">",
"     14",
"    </a>",
"    ]. Blood and urine samples are generally required; timing of collection of urine samples may be critical for maximal detection. Analysis of specific segments of hair can also be analyzed for drugs and correlated with timing of a past assault [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Samples should be analyzed by forensic laboratories rather than the laboratory of the examining facility.",
"   </p>",
"   <p>",
"    It remains important to maintain a chain of custody though these samples are separate from the evidence collection kit. Patients should understand that drug testing may also reveal voluntary drug or alcohol use which potentially can be used by defense to discredit victims [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures, soft tissue injuries, and other traumatic injuries should be treated appropriately. In one series, hospital admission was required more often in older than younger women, with 15.7 percent of women over 55 hospitalized [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After urgent attention to trauma, the remainder of the initial treatment regimen should focus upon sexually transmitted diseases (including hepatitis B and HIV) and psychosocial issues (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Psychosocial issues'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy regarding empiric prophylactic postexposure treatment for sexually transmitted infections. However, the United States Centers for Disease Control and Prevention (CDC) and others recommend empiric antibiotic prophylaxis since many assault victims will not return for a follow-up visit, and treatment based upon culture results is therefore problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. In addition, patients often prefer immediate treatment.",
"   </p>",
"   <p>",
"    The risk of acquiring a sexually transmitted infection is difficult to measure due to the poor follow-up in many studies, and the fact that an infection transmitted during an assault may be present during the baseline examination since the initial evaluation can occur days after the event. The risk of chlamydial infection is estimated to be 3 to 16 percent, with an 11 percent risk of pelvic inflammatory disease and bacterial vaginosis, and a 7 percent risk of trichomoniasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric therapy includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    250 mg IM or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    400 mg PO for gonorrhea and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    1 gram PO (single dose) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg PO twice daily for seven days for chlamydia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    2 grams PO (single dose) is also recommended to treat trichomoniasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link&amp;anchor=H13#H13\">",
"     \"Trichomonas vaginalis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link&amp;anchor=H5622559#H5622559\">",
"     \"Treatment of Chlamydia trachomatis infection\", section on 'Treatment of uncomplicated genital chlamydia infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hepatitis B infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends postexposure hepatitis B vaccination without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) as adequate protection against hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/24\">",
"     24",
"    </a>",
"    ]. If the assailant is known to be hepatitis B infected, HBIG is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/30\">",
"     30",
"    </a>",
"    ]. Follow-up doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    should be administered one and six months after the first dose. Vaccination is not necessary if the patient has had previous hepatitis B vaccine and documented immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic treatment with antiviral drugs for HIV following sexual assault is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/25,31\">",
"     25,31",
"    </a>",
"    ], although there is consensus that the risks and benefits of HIV prophylaxis should be addressed with every patient. There are no good data on the risk of acquiring HIV from an unknown assailant, although there are case reports of HIV transmission after sexual assault [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk of HIV transmission from a single episode of consensual vaginal intercourse with an HIV infected man is estimated at 0.1 percent, and from a single episode of consensual anal intercourse at 2 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    .) The risk of transmission after sexual assault by an HIV infected man is likely to be higher, since there may be associated trauma and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most assailants from countries with low population seroprevalence rates are unlikely to be infected with HIV. In a study of men incarcerated at a Rhode Island state prison from 1994 to 1999, of 1524 charged with a sexual offense only 1 percent were infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/32\">",
"     32",
"    </a>",
"    ]. Other data, however, indicate that Rhode Island prison inmates overall had a low prevalence of HIV in 1994 compared with New York State inmates (3.8 percent versus 12.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/33\">",
"     33",
"    </a>",
"    ]. HIV seroprevalence rates among prisoners have since declined nationally. The highest prevalence in 2008 was 5.9 percent in New York State, with many states reporting rates less than one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the overall risk of acquiring HIV after an assault by an unknown assailant is likely low, the risk may be increased by certain aspects of the assault:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male on male rapists might be expected to have a higher prevalence of HIV infection",
"     </li>",
"     <li>",
"      Sexual assault in a region or country with a high background prevalence of HIV increases the likelihood that an assailant will be HIV infected",
"     </li>",
"     <li>",
"      Multiple assailants presumably increase the risk, since any of the assailants might be infected with HIV",
"     </li>",
"     <li>",
"      Anal sexual assault may be more likely to transmit HIV",
"     </li>",
"     <li>",
"      Sexual assault where either the assailant or the victim has trauma, bleeding, or genital lesions may increase the likelihood of transmission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the presumed low risk of transmission and the lack of evidence proving the efficacy of antiretroviral drugs after sexual assault, most believe that they should be offered.",
"   </p>",
"   <p>",
"    Generalizing from the model of occupational HIV exposure, it is thought that antiretroviral drugs are best started within four hours of assault, and should probably not be prescribed if more than 72 hours has passed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/31\">",
"     31",
"    </a>",
"    ]. Options for prophylactic regimens used in postexposure prophylaxis (PEP) for healthcare workers are suitable for patients who choose to take HIV prophylactic treatment following sexual assault. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of healthcare personnel exposed to HIV\", section on 'Postexposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest consultation with a specialist familiar with PEP regimens. The United States Centers for Disease Control (CDC) recommends that patients be given an initial prescription for PEP for only three to seven days, with short-term follow-up for further counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of pregnancy after a single episode of vaginal intercourse varies during the menstrual cycle (",
"    <a class=\"graphic graphic_table graphicRef58851 \" href=\"UTD.htm?0/33/539\">",
"     table 1",
"    </a>",
"    ). Postcoital emergency contraception should be offered without regard to the menstrual cycle, given the uncertainty in the timing of ovulation.",
"   </p>",
"   <p>",
"    In the United States, available regimens for emergency contraception include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    alone, the Yuzpe regimen and the progestin",
"    <span class=\"nowrap\">",
"     antagonist/agonist",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     ulipristal",
"    </a>",
"    . Levonorgestrel (0.75 mg and repeated in 12 hours, or 1.5 mg as a single dose) is more effective than the Yuzpe regimen and is associated with fewer side effects. The Yuzpe regimen (100 mcg of ethinyl estradiol and 0.5 mg of levonorgestrel given as two Ovral contraceptive pills or its equivalent and repeated in 12 hours) is 75 to 80 percent effective if administered within 72 hours of intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/36\">",
"     36",
"    </a>",
"    ]. Ulipristal, where available, is effective up to 120 hours after intercourse and is the preferred drug beyond 72 hours after unprotected intercourse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outside of the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (600 mg single dose) is also available for emergency contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients will experience nausea and vomiting from the combination of antibiotics and contraceptives; antiemetics should be offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual assault victims require extensive emotional support and should be offered mental health services. Symptoms may include anger, fear, anxiety, physical pain, sleep disturbance, anorexia, shame, guilt, and intrusive thoughts.",
"   </p>",
"   <p>",
"    Additionally, they may experience musculoskeletal, genital, pelvic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal pain. Anorexia and insomnia can persist. Dreams and nightmares are common, and phobias may develop. Victims may find it very difficult to resume their habits, lifestyles, and sexual relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients may develop posttraumatic stress disorder, depression, or anxiety syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The medical evaluation and evidence collection process itself can be traumatizing and may compound the victim's sense of shame and loss of control. Providers should not force evaluation or treatment and should allow the victim some control in the evaluation process. A chaperone or advocate should be present during the evaluation.",
"   </p>",
"   <p>",
"    Acute crisis counseling should include safety planning. Victims should be referred for ongoing counseling ideally through sexual assault crisis programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific forensic forms should be included in evidence collection kits. These forms are used even if evaluation and treatment occur without evidence collection. Keeping the sexual assault report separate from the medical record is customary and has a precedent in psychiatric records. A face sheet documenting a &ldquo;medical legal examination&rdquo; is usually all that is needed in most states. Victims have serious concerns about access to the medical legal examination and photographs; appropriate advice should be given and consent obtained before the examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legal definitions, procedures, and reporting requirements vary by state. Some states do not define sexual assault to include male victims and prosecution must occur under sodomy or other statutes. In most states, only rapes involving children or elders require reporting by providers, while others require mandatory reporting for any sexual assault. Even when reporting is mandatory, victims can remain anonymous for examination and reporting purposes (eg, Jane Doe). Successful prosecution appears to be associated with evaluation within 24 hours of assault, performance of a physical examination, documentation of anogenital trauma and other injury, the use of a weapon, and assault in the context of an intimate relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence should be collected at the time of the initial evaluation and stored securely even if the patient is not planning to report the assault. Victims must sign consent forms prior to evidence collection. In addition, victims should be notified when the evidence is to be destroyed if there is no police involvement.",
"   </p>",
"   <p>",
"    Many states have witness assistance programs to provide advice on reporting, navigating the legal system, and victim financial compensation. Conviction rates range from 8 to 20 percent in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/28\">",
"     28",
"    </a>",
"    ]. Examiners should anticipate that they may be called to testify if a case is prosecuted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up medical visit should occur within one to two weeks of the acute evaluation. This provides an opportunity to check about psychosocial supports for the victim and to offer counseling. If treatment for STDs was not initially provided, a medical visit at one week is necessary to ensure follow-up of appropriate tests. At the follow-up visit, additional photographs of injuries can be taken to assess healing and document the time frame.",
"   </p>",
"   <p>",
"    Compliance with follow-up medical care is often poor among victims of assault. Describing the short duration of the follow-up examination and the reasons for the visit at the initial evaluation and enlisting support from victim advocates are important ways to improve compliance.",
"   </p>",
"   <p>",
"    Pregnancy testing should be performed (even if the patient received postcoital contraception). Testing for gonorrhea, chlamydia, trichomonas, and bacterial vaginosis should be done ideally one week after the assault in patients who declined prophylactic treatment. Testing is also indicated for those who develop interim symptoms, and in those who request testing.",
"   </p>",
"   <p>",
"    The CDC recommends that an RPR be rechecked at six weeks, three months, and six months and suggests that HIV post-exposure testing should be offered at the same intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/24\">",
"     24",
"    </a>",
"    ]. Others suggest that serologic reexamination be done at 12 and 24 weeks only [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients should be counseled to abstain from intercourse until prophylactic treatment is completed and consider condom use until serologic testing is completed. Hepatitis B vaccination should be given at one month and six months to complete primary vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Long-term implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with prior sexual assault are at increased risk for a number of psychological, physical, and behavioral adverse effects. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posttraumatic stress disorder, anxiety, depression, and suicide attempt [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Misuse of prescription sedatives, stimulants, steroids, and analgesics [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For women with PTSD, anxiety related to pelvic examination and avoidance of cervical cancer screening [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Irregular menses, pelvic pain, dyspareunia, and urinary infections [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased sexual satisfaction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased risk for cervical cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROVIDER PREPAREDNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A national protocol for sexual assault medical forensic evaluations of adults and adolescents is available on-line through the US Department of Justice, Office of Violence Against Women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Providers should learn about local resources for sexual assault victims before they are presented with a patient who has experienced assault. The following issues should be researched:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Who are the available Sexual Assault Nurse Examiners or other trained providers in the community? How can they be contacted?",
"     </li>",
"     <li>",
"      Are there cultural issues for members of the community which might require special adaptation for the evaluation of sexual assault? Are interpreters available?",
"     </li>",
"     <li>",
"      What are the local requirements for collection of evidence and for documentation? Evidence collection kits and forensic documentation forms should be available immediately when a patient presents needing evaluation.",
"     </li>",
"     <li>",
"      Is there a UV light source? Is a camera available? Is colposcopy available?",
"     </li>",
"     <li>",
"      What are the local requirements for toxicology screening for date rape drugs?",
"     </li>",
"     <li>",
"      What are the jurisdictional policies regarding mandatory reporting?",
"     </li>",
"     <li>",
"      What is the local contact for sexual assault crisis support services?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF PERPETRATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of repeat assault by sex offenders is decreased for those at increased age at the time of release from incarceration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/48\">",
"     48",
"    </a>",
"    ]. Studies of cognitive behavioral treatment to prevent recidivism in incarcerated sexual offenders report mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several different medications have been administered to decrease recidivism, including selective serotonin reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , and LHRH. LHRH may be the most effective treatment, although adverse effects include low bone density and gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20601/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/4/28738?source=see_link\">",
"       \"Patient information: Care after rape or sexual assault (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"       \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the US, one in three women will be a victim of sexual assault during her lifetime; seven to ten percent of sexual assault victims are male. Only 10 to 15 percent of sexual assaults are reported to the police. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of the sexual assault victim should be performed by a trained provider, if at all possible. A complete history should be documented. Evaluation should include psychological assessment, evaluation of areas of trauma, and examination of the breasts, pelvic and anorectal areas. Colposcopy should be performed, when possible, to detect genital trauma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An evidence collection kit, with detailed instruction and containers for specimen collection, is necessary for a forensic evaluation. The victim should be evaluated as soon as possible after an assault, but evidence may be collected at later times depending upon factors such as patient history and hygiene. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Forensic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for sexually transmitted disease (STD) is not necessary if prophylactic treatment is to be given. Laboratory testing should include pregnancy testing in women of childbearing age. Baseline serology for syphilis and hepatitis B may be useful and HIV counseling should be provided. Drug screening should be considered if the victim was unconscious. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric treatment of sexually transmitted infections should be considered, especially if the patient has declined testing for STD. Empiric therapy includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      250 mg IM for gonorrhea and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      1 gram PO (single dose) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg PO twice daily for seven days for chlamydia.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      2 grams PO (single dose) is also recommended to treat trichomoniasis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sexually transmitted infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       Hepatitis B vaccine",
"      </a>",
"      should be given to patients who have not been previously immunized. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hepatitis B infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic treatment for HIV is controversial. The risk of HIV transmission is low, and the efficacy of antiretroviral drugs is unknown, but most do recommend treatment if it can be initiated within 72 hours of exposure, and ideally within four hours. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postcoital contraception is recommended. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute crisis counseling should be offered. Many patients experience psychological and physical symptoms over many months following the assault. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Psychosocial issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient follow-up should occur by two weeks, with psychosocial counseling, STD testing for patients who did not take empiric therapy or who have symptoms, and pregnancy testing.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       Hepatitis B vaccine",
"      </a>",
"      should be given at one and six months to complete the vaccine course. HIV and RPR testing should be repeated at 12 and 24 weeks; some also recommend testing at six weeks. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3706942\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tjaden P, Thoennes N. Extent, nature, and consequences of rape victimization: Findings from the national violence against women survey. Department of Justice 2006. www.ncjrs.gov/pdffiles1/nij/210346.pdf (Accessed on January 29, 2010).",
"    </li>",
"    <li>",
"     Fisher BS, Cullen FT, Turner MG. The sexual victimization of college women. Department of Justice 2000. www.ncjrs.gov/pdffiles1/nij/182369.pdf (Accessed on January 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/3\">",
"      Lawyer S, Resnick H, Bakanic V, et al. Forcible, drug-facilitated, and incapacitated rape and sexual assault among undergraduate women. J Am Coll Health 2010; 58:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/4\">",
"      Eckert LO, Sugar NF. Older victims of sexual assault: an underrecognized population. Am J Obstet Gynecol 2008; 198:688.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/5\">",
"      Peterson ZD, Voller EK, Polusny MA, Murdoch M. Prevalence and consequences of adult sexual assault of men: review of empirical findings and state of the literature. Clin Psychol Rev 2011; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     Federal Bureau of Investigation Uniform Crime Reports. www.fbi.gov/ucr/ucr.htm (Accessed on August 27, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/7\">",
"      Burgess AW, Fawcett J. The comprehensive sexual assault assessment tool. Nurse Pract 1996; 21:66, 71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/8\">",
"      Jones JS, Alexander C, Wynn BN, et al. Why women don't report sexual assault to the police: the influence of psychosocial variables and traumatic injury. J Emerg Med 2009; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/9\">",
"      Linden JA. Clinical practice. Care of the adult patient after sexual assault. N Engl J Med 2011; 365:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/10\">",
"      Sexual assault; ACOG educational bulletin. Int J Gyn Obst 1997; 60:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/11\">",
"      Ramin SM, Satin AJ, Stone IC Jr, Wendel GD Jr. Sexual assault in postmenopausal women. Obstet Gynecol 1992; 80:860.",
"     </a>",
"    </li>",
"    <li>",
"     A national protocol for sexual assault medical forensic evaluations adults/adolescents.US Department of Justice, Office of Violence Against Women. September 2004, NCJ 206554. www.ncjrs.org/pdffiles1/ovw/206554.pdf (Accessed on September 13, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/13\">",
"      Maguire W, Goodall E, Moore T. Injury in adult female sexual assault complainants and related factors. Eur J Obstet Gynecol Reprod Biol 2009; 142:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/14\">",
"      J&auml;nisch S, Meyer H, Germerott T, et al. Analysis of clinical forensic examination reports on sexual assault. Int J Legal Med 2010; 124:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/15\">",
"      Slaughter L, Brown CR, Crowley S, Peck R. Patterns of genital injury in female sexual assault victims. Am J Obstet Gynecol 1997; 176:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/16\">",
"      Drocton P, Sachs C, Chu L, Wheeler M. Validation set correlates of anogenital injury after sexual assault. Acad Emerg Med 2008; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/17\">",
"      Hampton HL. Care of the woman who has been raped. N Engl J Med 1995; 332:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/18\">",
"      Ciancone AC, Wilson C, Collette R, Gerson LW. Sexual Assault Nurse Examiner programs in the United States. Ann Emerg Med 2000; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     North Dakota Sexual Assault Evidence Collection Protocol. 4th edition, May 2005. www.ndcaws.org/assault/2004%20CASAND%20Protocol%20-%20final.pdf (Accessed on September 27, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/20\">",
"      Carr ME, Moettus AL. Developing a policy for sexual assault examinations on incapacitated patients and patients unable to consent. J Law Med Ethics 2010; 38:647.",
"     </a>",
"    </li>",
"    <li>",
"     www.ovw.usdoj.gov/ovw-fs.htm (Accessed on June 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/22\">",
"      Young WW, Bracken AC, Goddard MA, Matheson S. Sexual assault: review of a national model protocol for forensic and medical evaluation. New Hampshire Sexual Assault Medical Examination Protocol Project Committee. Obstet Gynecol 1992; 80:878.",
"     </a>",
"    </li>",
"    <li>",
"     Hammer RM, Moynihan B, Pagliaro EM. Forensic Nursing: A Handbook for Practice, Jones and Bartlett, Sudbury 2006. p.570.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/24\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/25\">",
"      Gostin LO, Lazzarini Z, Alexander D, et al. HIV testing, counseling, and prophylaxis after sexual assault. JAMA 1994; 271:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/26\">",
"      Rossi R, Lancia M, Gambelunghe C, et al. Identification of GHB and morphine in hair in a case of drug-facilitated sexual assault. Forensic Sci Int 2009; 186:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/27\">",
"      Gaulier JM, Sauvage FL, Pauthier H, et al. Identification of acepromazine in hair: an illustration of the difficulties encountered in investigating drug-facilitated crimes. J Forensic Sci 2008; 53:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/28\">",
"      Rambow B, Adkinson C, Frost TH, Peterson GF. Female sexual assault: medical and legal implications. Ann Emerg Med 1992; 21:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/29\">",
"      Glaser JB, Schachter J, Benes S, et al. Sexually transmitted diseases in postpubertal female rape victims. J Infect Dis 1991; 164:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/30\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/31\">",
"      Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/32\">",
"      Rich JD, Macalino G, Merchant RC, et al. HIV seroprevalence of adult males incarcerated for a sexual offense in Rhode Island, 1994-1999. JAMA 2002; 288:164.",
"     </a>",
"    </li>",
"    <li>",
"     HIV in prisons, 1994. Bureau of Justice Statistics Bulletin, March 1996, NCJ -158020. www.ojp.usdoj.gov/bjs/pub/pdf/hivip94.pdf (Accessed on September 03, 2006).",
"    </li>",
"    <li>",
"     HIV in prisons, 2007-2008. Bureau of Justice Statistics Bulletin, December 2009, NCJ-228307. file://bjs.ojp.usdoj.gov/content/pub/pdf/hivp08.pdf (Accessed on December 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/35\">",
"      Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/36\">",
"      Glasier A. Emergency postcoital contraception. N Engl J Med 1997; 337:1058.",
"     </a>",
"    </li>",
"    <li>",
"     Burgess AW, Holmstrom LL. Rape: Crisis and Recovery, Robert J. Brady Co, Bowie 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/38\">",
"      Wiley J, Sugar N, Fine D, Eckert LO. Legal outcomes of sexual assault. Am J Obstet Gynecol 2003; 188:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/39\">",
"      McGregor MJ, Du Mont J, Myhr TL. Sexual assault forensic medical examination: is evidence related to successful prosecution? Ann Emerg Med 2002; 39:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/40\">",
"      Gray-Eurom K, Seaberg DC, Wears RL. The prosecution of sexual assault cases: correlation with forensic evidence. Ann Emerg Med 2002; 39:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/41\">",
"      Belik SL, Stein MB, Asmundson GJ, Sareen J. Relation between traumatic events and suicide attempts in Canadian military personnel. Can J Psychiatry 2009; 54:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/42\">",
"      McCauley JL, Amstadter AB, Danielson CK, et al. Mental health and rape history in relation to non-medical use of prescription drugs in a national sample of women. Addict Behav 2009; 34:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/43\">",
"      Weitlauf JC, Finney JW, Ruzek JI, et al. Distress and pain during pelvic examinations: effect of sexual violence. Obstet Gynecol 2008; 112:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/44\">",
"      Mark H, Bitzker K, Klapp BF, Rauchfuss M. Gynaecological symptoms associated with physical and sexual violence. J Psychosom Obstet Gynaecol 2008; 29:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/45\">",
"      Campbell R, Lichty LF, Sturza M, Raja S. Gynecological health impact of sexual assault. Res Nurs Health 2006; 29:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/46\">",
"      McCall-Hosenfeld JS, Liebschutz JM, Spiro A, Seaver MR. Sexual assault in the military and its impact on sexual satisfaction in women veterans: a proposed model. J Womens Health (Larchmt) 2009; 18:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/47\">",
"      Coker AL, Hopenhayn C, DeSimone CP, et al. Violence against Women Raises Risk of Cervical Cancer. J Womens Health (Larchmt) 2009; 18:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/48\">",
"      Prentky RA, Lee AF. Effect of age-at-release on long term sexual re-offense rates in civilly committed sexual offenders. Sex Abuse 2007; 19:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/49\">",
"      Craig, LA, Browne, KD, Stringer, I. Treatment and sexual offence recidivism. Trauma Violence Abuse 2003; 4:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20601/abstract/50\">",
"      Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J Clin Psychiatry 2003; 64:890.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2765 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20601=[""].join("\n");
var outline_f20_7_20601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95143399\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2401136\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2401080\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Trained providers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Forensic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Perpetrator evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hepatitis B infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Legal issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Long-term implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROVIDER PREPAREDNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF PERPETRATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3706942\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/2765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/2765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/33/539\" title=\"table 1\">",
"      Probability of pregnancy after unprotected intercourse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/4/28738?source=related_link\">",
"      Patient information: Care after rape or sexual assault (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=related_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20602="Child abuse: Eye findings in children with abusive head trauma (AHT)";
var content_f20_7_20602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Child abuse: Eye findings in children with abusive head trauma (AHT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20602/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20602/contributors\">",
"     Brian Forbes, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20602/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20602/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/7/20602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/7/20602/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/7/20602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abusive head trauma (AHT) is also known as nonaccidental head injury, inflicted head injury, or inflicted childhood neurotrauma. One subset is referred to as shaken baby syndrome, with a constellation of inflicted injuries in young children characterized by repeated acceleration-deceleration injury with or without blunt head impact [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Characteristic clinical features include retinal hemorrhages (often bilateral, multilayered, and extensive), subdural hematoma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occult fractures (particularly of the ribs and long bone metaphyses). Multiple episodes of trauma may occur before the abuse is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Early recognition can be lifesaving.",
"   </p>",
"   <p>",
"    The ophthalmologic aspects of abusive head trauma will be reviewed here. The pathogenesis of retinal hemorrhages in AHT, other aspects of AHT, and the management of suspected child abuse are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7718?source=see_link\">",
"       \"Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"       \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child abuse is an important cause of death in children. Among child abuse fatalities, head injury is the leading cause of death in infancy. Mortality rates in series of cases of AHT range from approximately 15 to 25 percent. The epidemiology and risk factors for physical abuse and abusive head trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H23#H23\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with AHT commonly have abnormal eye findings such as hemorrhages of the retina, vitreous, or optic nerve sheath and perimacular retinal folding or retinoschisis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/9\">",
"     9",
"    </a>",
"    ]. For example, in a systematic review of 20 observational studies with results of eye examination in 973 victims of abuse, intraocular hemorrhage (retinal or vitreous hemorrhage) was seen in approximately 85 percent of children with AHT. Thus, a careful funduscopic examination, preferably by an ophthalmologist is indicated in all children in whom AHT is suspected. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ophthalmology consultation'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AHT often requires a high index of suspicion. An accurate history is rarely provided at the time of presentation. The signs and symptoms can vary from mild and nonspecific to severe and immediately life-threatening. AHT should be suspected in infants who present with unexplained vomiting, poor feeding, lethargy, irritability, seizures, impaired consciousness, or apnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H2#H2\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonophthalmologic aspects of the physical examination of the infant with inflicted head injury are discussed separately and often involve abnormal findings on examination of the skin, chest, and abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H4#H4\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial eye examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmologic examination is essential when evaluating young children whose injuries are suspicious for child abuse. Poorly reactive pupils or a gaze preference may be noted. Periorbital ecchymoses, subconjunctival hemorrhage (especially in the absence of coughing or vomiting in infants over four weeks), hyphema, and orbital fractures may indicate direct trauma to the face or orbit, whereas funduscopic findings such as retinal hemorrhages may indicate occult intracranial injury. Late signs of severe direct injury on funduscopy may include optic atrophy, retinal detachment, retinal scars, and choroidal rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9783?source=see_link\">",
"     \"Orbital fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability to detect retinal hemorrhages and other abnormalities of the fundus depends upon the technique that is used to examine the retina:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Dilated examination",
"      </strong>",
"      &ndash; Pupillary constriction, which may result from the administration of barbiturates for sedation or narcotics for pain control, can limit the yield of the retinal examination, even with an indirect ophthalmoscope. Pharmacologic dilation (",
"      <a class=\"graphic graphic_table graphicRef57408 \" href=\"UTD.htm?40/33/41499\">",
"       table 1",
"      </a>",
"      ) of the pupils facilitates detection of retinal hemorrhages and other abnormalities, as well as retinal photography. These benefits of pharmacologic dilation usually outweigh the loss of ability to monitor pupillary reaction for several hours. Dilating one eye at a time may be an alternative in situations where the ability to monitor pupillary reaction is necessary (eg, patients with signs of severe increased intracranial pressure) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Direct ophthalmoscopy",
"      </strong>",
"      &ndash; The handheld direct ophthalmoscope provides a magnified but limited view of the fundus: little more than 1 disk diameter can be visualized (",
"      <a class=\"graphic graphic_picture graphicRef71156 \" href=\"UTD.htm?12/9/12447\">",
"       picture 1",
"      </a>",
"      ). Extensive retinal hemorrhages in the posterior pole of the fundus in children with severe neurologic injury (and fixed dilated pupils) may be visualized, but more subtle findings in children with less severe injury may be missed [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"       12",
"      </a>",
"      ]. A newer type of handheld direct ophthalmoscope (the Pan Optic&trade; by Welch Allyn) increases the field of vision to 2 to 5 disk diameters and may increase the ability to detect retinal abnormalities with direct ophthalmoscopy. However, this has not been rigorously evaluated in controlled trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Indirect ophthalmoscopy &ndash;",
"      </strong>",
"      The indirect ophthalmoscope, most often a head-mounted unit with a hand-held lens, provides a wide-angle binocular view that simultaneously includes nearly all of the areas in the posterior pole of the fundus (",
"      <a class=\"graphic graphic_picture graphicRef71156 \" href=\"UTD.htm?12/9/12447\">",
"       picture 1",
"      </a>",
"      ). By directing the view toward different parts of the retina, much of the periphery can be seen. In an uncooperative child who is moving his or her eyes, the fundus image may flash past the viewer. The larger field of view provided by the indirect ophthalmoscope increases the likelihood that important features such as the optic nerve head or hemorrhages will come into view.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Postmortem examination",
"      </strong>",
"      &ndash; Postmortem examination of the eyes can reveal signs of possible child abuse and should be performed in cases of suspected abuse or unexplained death in infants and young children [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/13\">",
"       13",
"      </a>",
"      ]. Postmortem ocular examination supplements premortem findings and should be performed even if the eyes were examined clinically before death [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/14\">",
"       14",
"      </a>",
"      ]. Pathologic examination of the eyes and orbital tissues, which necessitates removal at autopsy, is also recommended in these patients to assure that all abnormalities are identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retinal findings, such as retinal hemorrhages, may be detected by any physician who is familiar with such hemorrhages and has experience with funduscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ]. Clinicians other than ophthalmologists may also dilate the pupils to improve their view (",
"    <a class=\"graphic graphic_table graphicRef57408 \" href=\"UTD.htm?40/33/41499\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, detection of intraocular abnormalities is optimized by ophthalmology consultation, which allows for full viewing of the retina with an indirect ophthalmoscope and dilation of the child's pupils. For example, in a retrospective series of 123 children admitted for subdural hematomas caused by abuse, physicians other than ophthalmologists failed to detect retinal hemorrhages in 29 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/16\">",
"     16",
"    </a>",
"    ]. In another series, no attempt was made by clinicians other than ophthalmologists to visualize the retina in 36 percent of patients with AHT; among the children who were examined, hemorrhages were missed in 13 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, consultation with an ophthalmologist should occur for all children under five years of age with suspected AHT regardless of initial findings on funduscopic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ophthalmology consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with an ophthalmologist for a complete dilated indirect funduscopic examination is recommended in all children younger than five years of age in whom AHT is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/13\">",
"     13",
"    </a>",
"    ]. The examination should take place within 24 to 72 hours so that transient retinal changes are not missed. The detection of retinal hemorrhages may be a crucial step in the identification of abuse and appropriate direction of additional evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consultation with an ophthalmologist is recommended whether or not retinal hemorrhages are detected by other clinicians. The ophthalmologist may be able to detect additional hemorrhages and characterize them in a fashion that allows for better assessment of the likelihood that child abuse occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The ophthalmologist also can provide a more knowledgeable opinion regarding the etiology of the retinal findings and better photographic documentation (if available) of the hemorrhages for legal purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Occasionally, intracranial abnormalities, including subdural hemorrhage, subarachnoid hemorrhage, and cerebral edema, may be missed on initial computed tomography scans of the head or may not be present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. In such cases, the detection of retinal hemorrhages is a strong indicator that AHT may still have occurred and prompt additional neuroimaging such as magnetic resonance imaging.",
"   </p>",
"   <p>",
"    Observational studies suggest that the frequency of retinal hemorrhages is low in young children with normal neuroimaging and no evidence of head trauma upon physical examination. However, an eye examination by an ophthalmologist is not invasive and seems warranted, if available, and suspicion for abusive head trauma is high enough that a skeletal survey or neuroimaging is obtained. Furthermore, in children who do not receive eye examination by an ophthalmologist, determination that there are no significant findings of child abuse should only occur after consultation with a child abuse specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H4437991#H4437991\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Ophthalmologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OPHTHALMOLOGIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmologic findings of AHT may include retinal hemorrhages, retinal folds, retinoschisis (ie, splitting of the retina), vitreous hemorrhage, papilledema, optic nerve sheath hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    optic atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Retinal hemorrhages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal hemorrhages are seen in 47 to 100 percent of cases of AHT, with a frequency of approximately 85 percent in most case series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/9,12,16,19,25-33\">",
"     9,12,16,19,25-33",
"    </a>",
"    ]. Retinal hemorrhage is most commonly found on autopsy and least common among children with normal neurologic outcome.",
"   </p>",
"   <p>",
"    The finding of retinal hemorrhage on ophthalmologic examination significantly increases suspicion for inflicted injury, but does not necessarily confirm the diagnosis nor does the absence of retinal hemorrhage exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/9,15,16,34-37\">",
"     9,15,16,34-37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Description and severity",
"      </strong>",
"      &ndash; When describing retinal hemorrhages, it is important to describe the number of hemorrhages, the pattern of distribution, and the type of hemorrhage (",
"      <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68695 \" href=\"UTD.htm?23/8/23683\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef64277 \" href=\"UTD.htm?21/18/21795\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54695 \" href=\"UTD.htm?2/18/2339\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,32\">",
"       12,32",
"      </a>",
"      ]. The types and severity of hemorrhages have diagnostic and prognostic implications [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The severity of the retinal abnormalities is also correlated with the severity of the intracranial abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Retinal hemorrhages in AHT usually are bilateral, although asymmetry and unilaterality are well recognized [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,16,27,30,31,34,38\">",
"       12,16,27,30,31,34,38",
"      </a>",
"      ]. In a series of 75 children with AHT, there was no correlation between the laterality of intracranial findings (eg, extra-axial hemorrhage, edema) and the laterality of retinal findings [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/27\">",
"       27",
"      </a>",
"      ], although a correlation was detected in a smaller series (14 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the majority of cases of AHT (approximately two-thirds), the hemorrhages are too numerous to count and extend to the ora serrata (",
"      <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/16\">",
"       16",
"      </a>",
"      ]. However, retinal hemorrhages associated with AHT can be few in number, exclusively intraretinal, and confined to the posterior pole.",
"      <br/>",
"      <br/>",
"      In approximately two-thirds of cases of AHT, retinal hemorrhage occurs in multiple layers (eg, preretinal, intraretinal, and subretinal) (",
"      <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"       12",
"      </a>",
"      ]. Less commonly, patients also have vitreous hemorrhages. Dense preretinal or vitreous hemorrhages may obscure underlying retinal hemorrhage.",
"      <br/>",
"      <br/>",
"      Many patients have white-centered hemorrhages that appear to be caused by fibrin plugs, ischemia, or central resolution (",
"      <a class=\"graphic graphic_picture graphicRef69742 \" href=\"UTD.htm?8/20/8512\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/16,40\">",
"       16,40",
"      </a>",
"      ]. These white-centered hemorrhages should not be described as Roth spots because doing so falsely implies an infectious origin (ie, endocarditis), which may confuse the child's evaluation.",
"      <br/>",
"      <br/>",
"      Grading of retinal hemorrhages tends to be subjective and no universally recognized standard exists. One grading scale for retinal hemorrhage developed by the author uses the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      &ndash; Limited intraretinal or&nbsp;preretinal hemorrhage primarily in a perivascular or peripapillary pattern. Can include only minimal intraretinal hemorrhages in the macula,&nbsp;midperiphery or far periphery.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      &ndash; Intraretinal,&nbsp;preretinal and&nbsp;subretinal hemorrhages scattered throughout the retina which can be quantified. Papilledema can be present but not vitreous hemorrhage or hemorrhagic macular cysts.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      &ndash; Too numerous to count retinal hemorrhages in all layers of the retina. Presence of hemorrhagic macular cyst greater than 2 optic disk diameters in area. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinical course",
"      </strong>",
"      &ndash; Retinal hemorrhages cannot be accurately dated to determine the timing of the traumatic event [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"       12",
"      </a>",
"      ]. The time to resolution depends, to some extent, upon the hemorrhage size and type. Resolution can occur within a few days or may require several months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/16,41\">",
"       16,41",
"      </a>",
"      ]. Flame hemorrhages generally resolve faster than preretinal hemorrhages; blood in a schisis cavity resolves more slowly; vitreal hemorrhages are the slowest to resolve. Retinal scars and optic atrophy suggest previous injury.",
"      <br/>",
"      <br/>",
"      In a review of 30 cases of AHT, retinal hemorrhages (the type of which was not specified) resolved by four months in 18 of 20 survivors who were available for follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/41\">",
"       41",
"      </a>",
"      ]. In the remaining two patients, the hemorrhages resolved by 9 and 11 months, respectively. Another retrospective review included 123 children with AHT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/16\">",
"       16",
"      </a>",
"      ]. Although the timing of hemorrhage resolution was not specifically studied, the authors noted that small splinter hemorrhages disappeared within three to seven days in two children, and large preretinal hemorrhages slowly decreased in diameter over several weeks in four patients.",
"      <br/>",
"      <br/>",
"      Because of the marked variability in resolution time, retinal hemorrhages should not be used to estimate the date of injury, except perhaps in very broad terms (ie, fading hemorrhages are unlikely to be a few hours old, and extensive intraretinal hemorrhages are unlikely to be many months) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,31\">",
"       12,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Retinal folds and retinoschisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circular retinal folds centered on the macula (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 5",
"    </a>",
"    ) are a distinctive but not pathognomonic finding in AHT (",
"    <a class=\"graphic graphic_picture graphicRef54434 \" href=\"UTD.htm?10/40/10894\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/1,16,42-45\">",
"     1,16,42-45",
"    </a>",
"    ]. Retinal folds also have been reported after fatal motor vehicle crashes and crush head injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/43,44,46\">",
"     43,44,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnostic implications of eye findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both peripheral and macular traumatic retinoschisis (ie, splitting of the retina) may occur in AHT (",
"    <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"     figure 1",
"    </a>",
"    ). Macular retinoschisis, also called \"hemorrhagic macular cyst\", appears as a dense macular hemorrhage within the schisis cavity, often with a meniscal interface between red blood cells and serum.",
"   </p>",
"   <p>",
"    In most cases of retinoschisis, only the internal limiting membrane",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nerve fiber layer (",
"    <a class=\"graphic graphic_figure graphicRef68854 \" href=\"UTD.htm?15/58/16294\">",
"     figure 6",
"    </a>",
"    ) is pulled away by the vitreous because the vitreous is firmly attached in infants, a finding that has been demonstrated by electroretinogram and ultrasonography. However, deeper schisis and even focal macular detachment can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/47\">",
"     47",
"    </a>",
"    ]. Histologic findings may include attachment of the vitreous at the edges of the lesion and depigmentation of the retinal pigmented epithelium underlying the folds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The schisis cavity is usually surrounded by a hypopigmented or hemorrhagic arc or elevated retinal fold (perimacular or paramacular circular folds) (",
"    <a class=\"graphic graphic_picture graphicRef54434 \" href=\"UTD.htm?10/40/10894\">",
"     picture 3",
"    </a>",
"    ). The retinal fold may be continuous (360 degrees), discontinuous, or just an arc. It may encompass only the macula or surround the entire posterior pole, including the optic nerve.",
"   </p>",
"   <p>",
"    It is important that the circumlinear edge abnormalities be recognized clinically, since these distinguish retinoschisis from preretinal (subhyaloid) hemorrhage, particularly when only the internal limiting membrane is elevated. Blood may break through the schisis wall into the preretinal space or vitreous, obscuring the edge changes of a cavity, which may become apparent only after the blood resolves.",
"   </p>",
"   <p>",
"    The presence of retinal folds implies severe injury that often results in death or neurologic sequelae, although some patients have had good visual recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/1,16,42,45\">",
"     1,16,42,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vitreous hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitreous hemorrhage can obscure fundus detail (",
"    <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"     figure 1",
"    </a>",
"    ). It can be present at the first examination shortly after injury or occur days later from rupture of the internal limiting membrane over a dome-shaped hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef69754 \" href=\"UTD.htm?38/62/39919\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Papilledema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papilledema takes 12 to 24 hours to develop in patients with increased intracranial pressure following head injury. Thus, papilledema noted at the initial presentation suggests delay in seeking care after AHT has occurred and is an ominous finding that is associated with high mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,16,28\">",
"     12,16,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Optic nerve sheath hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic nerve sheath hemorrhage is commonly present in patients with AHT and is not always accompanied by retinal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/7,16,48,49\">",
"     7,16,48,49",
"    </a>",
"    ]. It is also seen in patients with unintentional head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/9\">",
"     9",
"    </a>",
"    ]. Optic nerve sheath hemorrhage tends to be most prominent anteriorly and may not extend the length of the optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Optic nerve sheath hemorrhages frequently involve multiple layers of the optic nerve but often show a preponderance of hemorrhage in the subdural space [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/48,50,51\">",
"     48,50,51",
"    </a>",
"    ]. The extent of the optic nerve sheath hemorrhage does not necessarily correlate with the severity of the intraocular findings or the intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other orbital trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other evidence of acceleration-deceleration-induced orbital trauma found at autopsy includes optic nerve intradural hemorrhage, and hemorrhage in the orbital fat, cranial nerve sheaths, or extraocular muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMPLICATIONS OF EYE FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AHT is made on the basis of the entire clinical scenario, which typically includes injuries suspicious for abuse and a history that is inconsistent with the severity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    type of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/4,25,52\">",
"     4,25,52",
"    </a>",
"    ]. Thus, eye findings must be placed within the context of all clinical features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link&amp;anchor=H15#H15\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of 20 observational studies comprising ocular findings in 1948 children, including 242 children with unintentional head injury and 973 children with AHT as determined by perpetrator confession, third-party witness, legal decision, autopsy findings, or multidisciplinary assessment found the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraocular hemorrhage (IOH) was present in 44 to 100 percent of children with AHT but only 0 to 10 percent of children with unintentional head injury. The mean sensitivity of IOH for child abuse was 75 percent and the specificity, based upon the four prospective case-control studies in the review, was 94 percent (range 90 to 100 percent). The specificity for AHT was highest for IOH that was bilateral, preretinal, peripheral, and moderate to severe, ie, extending beyond the retinal pole and involving multiple retinal layers or the vitreous. All IOH in children with unintentional head injury were described as mild, such as confined to the posterior retinal pole and involving a single retinal layer.",
"     </li>",
"     <li>",
"      Perimacular retinal folds and retinoschisis were seen in a small portion of children with AHT and were more commonly seen on autopsy. When present, these findings were highly specific for AHT and were not described in any children with unintentional head injury or other diseases in this review. However, these findings have rarely been reported after unintentional head injury including crush injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/43\">",
"       43",
"      </a>",
"      ], fatal motor vehicle collisions (MVC) with severe rotational and deceleration injury [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/46\">",
"       46",
"      </a>",
"      ], and one fatal 11-meter fall injury, which also produced multiple skull fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/9\">",
"       9",
"      </a>",
"      ]. Thus, when macular retinoschisis or perimacular retinal folds are present in a child without a history of major trauma, the likelihood of AHT is very high.",
"     </li>",
"     <li>",
"      Optic nerve sheath hemorrhage was described in 50 percent of 311 children with AHT versus 29 percent of 42 children with unintentional head injury. Thus, this finding is less specific for the diagnosis of AHT than IOH, perimacular retinal folds, or macular retinoschisis. However, when optic nerve sheath hemorrhage is present without a history of major trauma, AHT is the most likely diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with concerning eye findings, additional injuries, including fractures in various stages of healing or without a trauma history on skeletal survey, intraabdominal injury (eg, liver laceration, duodenal hematoma or perforation) and intracranial hemorrhage, especially subdural hematoma, increases the certainty of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, when child abuse is suspected and concerning eye findings are present, additional evaluation (eg, liver enzyme studies, computed tomography of the abdomen with intravenous contrast, neuroimaging, skeletal survey depending upon the child&rsquo;s age) is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions may result in retinal hemorrhages in infants and young children (",
"    <a class=\"graphic graphic_table graphicRef81915 \" href=\"UTD.htm?4/39/4734\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/11,12,30-32\">",
"     11,12,30-32",
"    </a>",
"    ]. AHT and perinatal hemodynamic changes are the most common diagnoses. Many other systemic and ocular conditions may be associated with retinal hemorrhages. Most of these entities have characteristic history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory features that distinguish them from AHT. As an example, in a prospective case series, 15 percent of critically ill children who did",
"    <strong>",
"     not",
"    </strong>",
"    have AHT had retinal hemorrhages on retinal photography or dilated examination by a pediatric ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/53\">",
"     53",
"    </a>",
"    ]. Most of these children had fewer than 5 single-layered retinal hemorrhages that were considered mild. The diagnoses in six children with more than 20 multi-layered retinal hemorrhages that were similar to those seen in AHT included fatal unintentional head trauma, severe coagulopathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis associated with myeloid leukemia.",
"   </p>",
"   <p>",
"    Having these conditions does not exclude the possibility of child abuse, which must be considered when the retinal hemorrhages have features associated with AHT (ie, numerous, multilayered, and extending to the retinal periphery) and other clinical findings of physical abuse (eg, subdural hematoma, liver laceration, fractures, skin bruising) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/11,12,30,35,36,54,55\">",
"     11,12,30,35,36,54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In observational studies, neither severe coughing, forceful vomiting (as in hypertrophic pyloric stenosis), nor seizures have been associated with retinal hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/30,56-58\">",
"     30,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Perinatal retinal hemorrhages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of perinatal retinal hemorrhages ranges from 20 to 30 percent among infants examined in the first 24 hours of life, and 10 to 15 percent among infants examined in the first 72 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,59,60\">",
"     12,59,60",
"    </a>",
"    ]. These hemorrhages appear to be related to peripartum prostaglandin release and obstetrical and perinatal hemodynamic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,59,61\">",
"     12,59,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraocular hemorrhages can occur with any type of delivery, including cesarean section, but they are particularly common in spontaneous vaginal or vacuum assisted deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"     12",
"    </a>",
"    ]. Perinatal retinal hemorrhages may be numerous and extend to the periphery, resembling those seen in AHT. Preretinal hemorrhage also may occur in neonates, but subretinal hemorrhage is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/32\">",
"     32",
"    </a>",
"    ]. Retinoschisis is not a finding associated with perinatal retinal hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of disappearance of perinatal retinal hemorrhage depends upon the size and type of hemorrhage: flame hemorrhages (",
"    <a class=\"graphic graphic_figure graphicRef68695 \" href=\"UTD.htm?23/8/23683\">",
"     figure 2",
"    </a>",
"    ) disappear within seven days, and",
"    <span class=\"nowrap\">",
"     dot/blot",
"    </span>",
"    hemorrhages (",
"    <a class=\"graphic graphic_figure graphicRef64277 \" href=\"UTD.htm?21/18/21795\">",
"     figure 3",
"    </a>",
"    ) typically resolve by four weeks (six weeks at most) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/59,62\">",
"     59,62",
"    </a>",
"    ]. Perinatal intrafoveal, preretinal (",
"    <a class=\"graphic graphic_figure graphicRef54695 \" href=\"UTD.htm?2/18/2339\">",
"     figure 4",
"    </a>",
"    ), and vitreous hemorrhage may last longer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Unintentional head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal hemorrhages have been reported in association with severe unintentional head injury (as may occur in a motor vehicle crash or fall from great height) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/34,36,54,63-66\">",
"     34,36,54,63-66",
"    </a>",
"    ]. However, clinical studies suggest that the rate of retinal hemorrhage in such injuries is low (usually less than 3 percent). In most series, the incidence of retinal hemorrhages after such injuries is zero, particularly when the mechanism of trauma is a short fall [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,34,36,55,64-69\">",
"     12,34,36,55,64-69",
"    </a>",
"    ]. Falls from sofas, out of the arms of caregivers, and during play rarely, if ever, cause retinal hemorrhages unless the mechanism of injury is severe (eg, falling off of a moving swing, falling through a stair rail at the top of a flight of stairs) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,63,70\">",
"     12,63,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When retinal hemorrhages occur in association with unintentional head injury, the history of trauma usually is clear and consistent, the mechanism of injury severe, other bodily injuries reflect the forces involved, and the infants have no additional unexplained injuries. The retinal hemorrhages typically are confined to the posterior pole, few in number, and rarely subretinal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"     12",
"    </a>",
"    ]. Retinoschisis and retinal folds have been rarely reported in cases of extreme accidental trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/43,44,46,50\">",
"     43,44,46,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hematologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulopathies and other bleeding disorders, including thrombocytopenia, severe anemia, leukemia, factor deficiencies, and vitamin K deficiency, should be considered in the differential diagnosis of intraocular hemorrhage in infants. Bleeding disorders usually are suggested by history, physical examination, and laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/11,12,31\">",
"     11,12,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe bleeding disorders can have intracranial bleeding, but few patients have retinal hemorrhages. In contrast to the retinal hemorrhages associated with AHT, the retinal hemorrhages associated with hematologic abnormalities usually are few in number and confined to the posterior pole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,71,72\">",
"     12,71,72",
"    </a>",
"    ]. Leukemia is a possible exception, but children with leukemia generally have additional clinical or laboratory abnormalities to readily suggest the diagnosis. Retinal examination often reveals leukemic infiltrates (",
"    <a class=\"graphic graphic_picture graphicRef77712 \" href=\"UTD.htm?33/14/34030\">",
"     picture 5",
"    </a>",
"    ) in addition to the hemorrhages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory evaluation for bleeding disorder should be performed in suspected cases of AHT with hemorrhagic manifestations unless there are obvious indicators of abuse (eg, pattern skin lesions, multiple unexplained fractures). Patients with abnormal laboratory findings may benefit from additional evaluation by a hematologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H7#H7\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Bleeding evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated coagulation factors may reflect underlying brain pathology, rather than a coagulation disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Brain injury can result in coagulopathy, which may be mild or severe (eg, disseminated intravascular coagulation). However, retinal hemorrhage in such patients without AHT is quite uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Trauma and extensive surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H13#H13\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1270279\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal hemorrhages have been described in some critically ill patients with sepsis, though in almost all cases, the patients had fewer than five retinal hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/53\">",
"     53",
"    </a>",
"    ].&nbsp; The three subjects with more than 20 retinal hemorrhages all had concomitant leukemia, in addition to severe sepsis.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraocular hemorrhage (IOH) may occur in association with intracranial hemorrhage (eg, from a ruptured aneurysm or arteriovenous malformation, or epidural hematoma) and subsequent elevated intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. Although the severity of the retinal hemorrhage is typically limited, ipsilateral severe hemorrhagic retinopathy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/80\">",
"     80",
"    </a>",
"    ]. This combination of retinal hemorrhage and intracranial hemorrhage is known as Terson syndrome and is uncommon in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,81,82\">",
"     12,81,82",
"    </a>",
"    ]. The presence of a vascular anomaly and the limited severity of IOH in patients with Terson syndrome help distinguish this diagnosis from AHT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"     \"Brain arteriovenous malformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Glutaric aciduria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutaric aciduria type 1 is an autosomal recessive metabolic disorder that is sometimes associated with subdural hemorrhage after minor head trauma. Preexisting macrocephaly is a hallmark of the condition. Glutaric aciduria eventually results in serious neurological compromise, but affected children may have normal development in early childhood. Approximately 20 percent of patients with glutaric aciduria type 1 have seizures, and 20 to 30 percent have subdural hemorrhages or effusions that may raise the suspicion of AHT. Children with glutaric aciduria may be more prone to subdural hemorrhage after minor accidental trauma because of increased extra-axial fluid spaces. Retinal hemorrhages may also occur, typically just a few pre- or intraretinal hemorrhages that are confined to the posterior pole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/83\">",
"     83",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H34#H34\">",
"     \"Organic acidemias\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to children with AHT, children with glutaric aciduria do not have bony abnormalities. Glutaric aciduria is diagnosed through urinary screening. Characteristic basal ganglia disease can develop even in the absence of significant changes in glutaric acid concentrations. The neuroimaging findings help to distinguish glutaric aciduria from AHT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H35#H35\">",
"     \"Organic acidemias\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chest compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely cardiopulmonary resuscitation or Purtscher retinopathy has been associated with mild retinal changes in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cardiopulmonary resuscitation (CPR)",
"      </strong>",
"      &ndash; Many infants with severe AHT undergo CPR, including chest compressions and artificial ventilation. However, retinal hemorrhages rarely, if ever, result from CPR [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12,30,54,84-86\">",
"       12,30,54,84-86",
"      </a>",
"      ]. In contrast to retinal hemorrhages associated with AHT, CPR-associated retinal hemorrhages are few in number and confined to the posterior pole.",
"     </li>",
"     <li>",
"      <strong>",
"       Purtscher retinopathy",
"      </strong>",
"      &ndash; A severe and abrupt increase in intrathoracic pressure may cause intraocular abnormalities, possibly related to complement activation, microemboli, nerve fiber infarcts (Purtscher retinopathy). Purtscher retinopathy may occur following severe acute compression injuries to the thorax, with characteristic manifestations including white retinal patches, few retinal hemorrhages, and retinal edema most commonly surrounding the optic disk.",
"      <br/>",
"      <br/>",
"      Purtscher retinopathy is not a characteristic finding of AHT, though it rarely may be seen (presumably related to the same compression of the thorax that results in rib fractures) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/87\">",
"       87",
"      </a>",
"      ]. The lack of a single case report of Purtscher retinopathy following CPR provides additional evidence that CPR with chest compression is an unlikely cause of retinal hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Sudden infant death syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden infant death syndrome (SIDS) is a common cause of death in children between 1 and 12 months of age. Children who die from SIDS may share several features with those who are victims of AHT, including the absence of explanatory history and the possibility of a prodromal syndrome such as gastrointestinal complaints. However, by definition, SIDS victims have no evidence of trauma by history, clinical examination, or autopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36872?source=see_link&amp;anchor=H13236298#H13236298\">",
"     \"Sudden unexpected infant death including SIDS: Initial management\", section on 'Fatal child abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, most deaths related to child abuse can be distinguished from SIDS by a complete autopsy, death scene investigation, and a review of the medical history. However, the autopsy cannot distinguish between accidental or deliberate asphyxiation with a soft object and SIDS although certain factors should raise the suspicion for deliberate asphyxiation and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36872?source=see_link&amp;anchor=H13236298#H13236298\">",
"     \"Sudden unexpected infant death including SIDS: Initial management\", section on 'Fatal child abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other conditions occasionally may be associated with retinal or vitreous hemorrhages in children and are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef81915 \" href=\"UTD.htm?4/39/4734\">",
"     table 2",
"    </a>",
"    ). However, the frequency of retinal hemorrhages in children with these conditions is extremely low [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"     12",
"    </a>",
"    ]. When retinal hemorrhages do occur in patients with these conditions, they typically are few in number and confined to the posterior pole. As with the conditions described above, these conditions usually have characteristic history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory features that distinguish them from AHT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with suspected physical abuse is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H19#H19\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ophthalmologic care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children who have eye findings of AHT require regular follow-up by an ophthalmologist. Children who have large, dome-shaped retinal hemorrhages require short-term follow-up (during the three to four weeks after injury), because the hemorrhages can break into the vitreous (",
"    <a class=\"graphic graphic_picture graphicRef69754 \" href=\"UTD.htm?38/62/39919\">",
"     picture 4",
"    </a>",
"    ). Large hemorrhages in the vitreous can interfere with vision and may cause amblyopia in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of amblyopia\", section on 'Deprivational amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitrectomy or intravitreal tissue plasminogen activator may be warranted in patients with large vitreal hemorrhages, particularly if the electrical response of the retina (electroretinogram) is good [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/47\">",
"     47",
"    </a>",
"    ]. However, even with these interventions, few patients with dense vitreous hemorrhages have been reported to see well after vitrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual potential in children with AHT is limited by retinal and central nervous system injuries (ie, cortical and optic atrophy). Within these limitations, the correction of refractive errors and treatment of amblyopia can help to maximize visual potential [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/89\">",
"     89",
"    </a>",
"    ]. Maximization of visual potential and visual learning ability can help to optimize overall outcome in survivors of AHT, who often have associated neurologic, cognitive, and psychologic handicaps, as well as visual compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/90\">",
"     90",
"    </a>",
"    ]. For children in whom vision cannot be improved, auditory and tactile learning can be promoted through early intervention programs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link&amp;anchor=H7#H7\">",
"     \"Children with special health care needs\", section on 'Development/learning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32679?source=see_link\">",
"     \"Support services for the care of chronically ill children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the child has normal vision and alignment three months after the injury, then the usual schedule of vision screening can be resumed as for any child. Persistent problems with strabismus and poor vision are followed as indicated by their severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening tests in children and adolescents\", section on 'Vision screen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation and management of strabismus in children\", section on 'Overview of management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmologic findings of AHT that are associated with increased mortality include poor vision on presentation, poor pupillary response, papilledema, and the presence of diffuse, retinal hemorrhages or retinal folds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/1,16,41,91\">",
"     1,16,41,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The visual potential in children with AHT is limited by central nervous system injuries and retinal injuries. Visual outcome is good (ie, visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better) in one-third to one-half of survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/5,41\">",
"     5,41",
"    </a>",
"    ]. Most intraretinal hemorrhages resolve spontaneously without sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/73\">",
"     73",
"    </a>",
"    ]. Large vitreal or preretinal hemorrhages may require intervention to prevent visual loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amblyopia. Foveal subretinal hemorrhages are associated with central scotoma. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Ophthalmologic care'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Vision loss is more often caused by brain injury than retinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/16,89\">",
"     16,89",
"    </a>",
"    ], although combined cerebral and ocular factors account for visual loss in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Bilateral retinal scarring can occur, both from retinoschisis and from retinal and vitreous hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/7/20602/abstract/47,88,94\">",
"     47,88,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consultation with an ophthalmologist for a complete dilated retinal examination is recommended in all children younger than five years of age in whom abusive head trauma (AHT) is suspected. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ophthalmology consultation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postmortem examination should be performed in cases of suspected abuse and unexplained deaths in infants and young children regardless of whether eye examination was conducted prior to death. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial eye examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ophthalmologic findings of abusive head trauma (AHT) may include retinal hemorrhages (",
"      <a class=\"graphic graphic_figure graphicRef61192 \" href=\"UTD.htm?34/42/35497\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69742 \" href=\"UTD.htm?8/20/8512\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69754 \" href=\"UTD.htm?38/62/39919\">",
"       picture 4",
"      </a>",
"      ), retinal folds and retinoschisis (",
"      <a class=\"graphic graphic_picture graphicRef54434 \" href=\"UTD.htm?10/40/10894\">",
"       picture 3",
"      </a>",
"      ), vitreous hemorrhage, papilledema, optic atrophy, and optic nerve sheath hemorrhage. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ophthalmologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most case series, the frequency of retinal hemorrhages in AHT is approximately 85 percent (range 50 to 100 percent). The finding of retinal hemorrhages increases the suspicion of inflicted injury but may not confirm the diagnosis, nor does the absence of retinal hemorrhage exclude the diagnosis. In approximately two-thirds of cases, retinal hemorrhages caused by AHT are bilateral, numerous, multilayered, and extend to the ora serrata (",
"      <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"       figure 5",
"      </a>",
"      ). Retinal hemorrhages cannot be accurately dated to determine the timing of the traumatic event. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Retinal hemorrhages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AHT is made on the basis of the entire clinical scenario, which typically includes injuries suspicious for abuse (eg, diffuse, extensive, multilayered retinal hemorrhages; subdural hematoma; fractures; bruises; intraabdominal injury [eg, liver laceration, duodenal hematoma or perforation]) and a history that is inconsistent with the severity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      type of injury. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnostic implications of eye findings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of conditions may result in retinal hemorrhages in infants and young children (",
"      <a class=\"graphic graphic_table graphicRef81915 \" href=\"UTD.htm?4/39/4734\">",
"       table 2",
"      </a>",
"      ). Most of these conditions have characteristic history, physical examination,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory features that distinguish them from AHT. In addition, when retinal hemorrhages occur in these conditions, they generally are few in number and confined to the posterior pole. Having these conditions does not preclude abusive injury. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of children with suspected physical abuse is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Young children who have ophthalmologic findings of AHT require regular follow-up by an ophthalmologist. The visual potential in children with AHT is limited by central nervous system injuries and retinal injuries. Visual outcome is good (ie, visual acuity of",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      or better) in one-third to one-half of survivors (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Ophthalmologic care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/1\">",
"      Mills M. Funduscopic lesions associated with mortality in shaken baby syndrome. J AAPOS 1998; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/2\">",
"      Lancon JA, Haines DE, Parent AD. Anatomy of the shaken baby syndrome. Anat Rec 1998; 253:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/3\">",
"      Caffey J. The whiplash shaken infant syndrome: manual shaking by the extremities with whiplash-induced intracranial and intraocular bleedings, linked with residual permanent brain damage and mental retardation. Pediatrics 1974; 54:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/4\">",
"      Christian CW, Block R, Committee on Child Abuse and Neglect, American Academy of Pediatrics. Abusive head trauma in infants and children. Pediatrics 2009; 123:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/5\">",
"      King WJ, MacKay M, Sirnick A, Canadian Shaken Baby Study Group. Shaken baby syndrome in Canada: clinical characteristics and outcomes of hospital cases. CMAJ 2003; 168:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/6\">",
"      Jenny C, Hymel KP, Ritzen A, et al. Analysis of missed cases of abusive head trauma. JAMA 1999; 281:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/7\">",
"      Lambert SR, Johnson TE, Hoyt CS. Optic nerve sheath and retinal hemorrhages associated with the shaken baby syndrome. Arch Ophthalmol 1986; 104:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/8\">",
"      Alexander R, Crabbe L, Sato Y, et al. Serial abuse in children who are shaken. Am J Dis Child 1990; 144:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/9\">",
"      Bhardwaj G, Chowdhury V, Jacobs MB, et al. A systematic review of the diagnostic accuracy of ocular signs in pediatric abusive head trauma. Ophthalmology 2010; 117:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/10\">",
"      Friendly DS. Ocular manifestations of physical child abuse. Trans Am Acad Ophthalmol Otolaryngol 1971; 75:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/11\">",
"      Kivlin JD. A 12-year ophthalmologic experience with the shaken baby syndrome at a regional children's hospital. Trans Am Ophthalmol Soc 1999; 97:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/12\">",
"      Levin AV. Ophthalmology of shaken baby syndrome. Neurosurg Clin N Am 2002; 13:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/13\">",
"      Levin AV, Christian CW, Committee on Child Abuse and Neglect, Section on Ophthalmology. The eye examination in the evaluation of child abuse. Pediatrics 2010; 126:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/14\">",
"      Wygnanski-Jaffe T, Levin AV, Shafiq A, et al. Postmortem orbital findings in shaken baby syndrome. Am J Ophthalmol 2006; 142:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/15\">",
"      American Academy of Pediatrics: Committee on Child Abuse and Neglect. Shaken baby syndrome: rotational cranial injuries-technical report. Pediatrics 2001; 108:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/16\">",
"      Kivlin JD, Simons KB, Lazoritz S, Ruttum MS. Shaken baby syndrome. Ophthalmology 2000; 107:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/17\">",
"      Morad Y, Kim YM, Mian M, et al. Nonophthalmologist accuracy in diagnosing retinal hemorrhages in the shaken baby syndrome. J Pediatr 2003; 142:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/18\">",
"      Morad Y, Avni I, Benton SA, et al. Normal computerized tomography of brain in children with shaken baby syndrome. J AAPOS 2004; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/19\">",
"      Minns RA, Jones PA, Tandon A, et al. Prediction of inflicted brain injury in infants and children using retinal imaging. Pediatrics 2012; 130:e1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/20\">",
"      D'Costa DF, Abbott RJ. Bilateral subdural haematomas and normal CT brain scans. Br J Clin Pract 1990; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/21\">",
"      Gudeman SK, Young HF, Miller JD, Becker DP. Bilateral acute subdural hematomas undiagnosed by computerized tomography: case report. Neurosurgery 1979; 5:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/22\">",
"      Levin AV, Magnusson MR, Rafto SE, Zimmerman RA. Shaken baby syndrome diagnosed by magnetic resonance imaging. Pediatr Emerg Care 1989; 5:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/23\">",
"      Feldman KW, Brewer DK, Shaw DW. Evolution of the cranial computed tomography scan in child abuse. Child Abuse Negl 1995; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/24\">",
"      Morad Y, Avni I, Capra L, et al. Shaken baby syndrome without intracranial hemorrhage on initial computed tomography. J AAPOS 2004; 8:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/25\">",
"      Duhaime AC, Christian CW, Rorke LB, Zimmerman RA. Nonaccidental head injury in infants--the \"shaken-baby syndrome\". N Engl J Med 1998; 338:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/26\">",
"      Green MA, Lieberman G, Milroy CM, Parsons MA. Ocular and cerebral trauma in non-accidental injury in infancy: underlying mechanisms and implications for paediatric practice. Br J Ophthalmol 1996; 80:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/27\">",
"      Morad Y, Kim YM, Armstrong DC, et al. Correlation between retinal abnormalities and intracranial abnormalities in the shaken baby syndrome. Am J Ophthalmol 2002; 134:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/28\">",
"      Rao N, Smith RE, Choi JH, et al. Autopsy findings in the eyes of fourteen fatally abused children. Forensic Sci Int 1988; 39:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/29\">",
"      Altman RL, Kutscher ML, Brand DA. The \"shaken-baby syndrome\". N Engl J Med 1998; 339:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/30\">",
"      Togioka BM, Arnold MA, Bathurst MA, et al. Retinal hemorrhages and shaken baby syndrome: an evidence-based review. J Emerg Med 2009; 37:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/31\">",
"      Forbes BJ, Christian CW, Judkins AR, Kryston K. Inflicted childhood neurotrauma (shaken baby syndrome): ophthalmic findings. J Pediatr Ophthalmol Strabismus 2004; 41:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/32\">",
"      Aryan HE, Ghosheh FR, Jandial R, Levy ML. Retinal hemorrhage and pediatric brain injury: etiology and review of the literature. J Clin Neurosci 2005; 12:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/33\">",
"      Binenbaum G, Mirza-George N, Christian CW, Forbes BJ. Odds of abuse associated with retinal hemorrhages in children suspected of child abuse. J AAPOS 2009; 13:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/34\">",
"      Duhaime AC, Alario AJ, Lewander WJ, et al. Head injury in very young children: mechanisms, injury types, and ophthalmologic findings in 100 hospitalized patients younger than 2 years of age. Pediatrics 1992; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/35\">",
"      Child abuse and the eye. The Ophthalmology Child Abuse Working Party. Eye (Lond) 1999; 13 ( Pt 1):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/36\">",
"      Bechtel K, Stoessel K, Leventhal JM, et al. Characteristics that distinguish accidental from abusive injury in hospitalized young children with head trauma. Pediatrics 2004; 114:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/37\">",
"      Pierre-Kahn V, Roche O, Dureau P, et al. Ophthalmologic findings in suspected child abuse victims with subdural hematomas. Ophthalmology 2003; 110:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/38\">",
"      Riffenburgh RS, Sathyavagiswaran L. Ocular findings at autopsy of child abuse victims. Ophthalmology 1991; 98:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/39\">",
"      Gilles EE, McGregor ML, Levy-Clarke G. Retinal hemorrhage asymmetry in inflicted head injury: a clue to pathogenesis? J Pediatr 2003; 143:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/40\">",
"      Kapoor S, Schiffman J, Tang R, et al. The significance of white-centered retinal hemorrhages in the shaken baby syndrome. Pediatr Emerg Care 1997; 13:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/41\">",
"      McCabe CF, Donahue SP. Prognostic indicators for vision and mortality in shaken baby syndrome. Arch Ophthalmol 2000; 118:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/42\">",
"      Massicotte SJ, Folberg R, Torczynski E, et al. Vitreoretinal traction and perimacular retinal folds in the eyes of deliberately traumatized children. Ophthalmology 1991; 98:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/43\">",
"      Lantz PE, Sinal SH, Stanton CA, Weaver RG Jr. Perimacular retinal folds from childhood head trauma. BMJ 2004; 328:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/44\">",
"      Lueder GT, Turner JW, Paschall R. Perimacular retinal folds simulating nonaccidental injury in an infant. Arch Ophthalmol 2006; 124:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/45\">",
"      Gaynon MW, Koh K, Marmor MF, Frankel LR. Retinal folds in the shaken baby syndrome. Am J Ophthalmol 1988; 106:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/46\">",
"      Kivlin JD, Currie ML, Greenbaum VJ, et al. Retinal hemorrhages in children following fatal motor vehicle crashes: a case series. Arch Ophthalmol 2008; 126:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/47\">",
"      Greenwald MJ, Weiss A, Oesterle CS, Friendly DS. Traumatic retinoschisis in battered babies. Ophthalmology 1986; 93:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/48\">",
"      Budenz DL, Farber MG, Mirchandani HG, et al. Ocular and optic nerve hemorrhages in abused infants with intracranial injuries. Ophthalmology 1994; 101:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/49\">",
"      Marshall DH, Brownstein S, Dorey MW, et al. The spectrum of postmortem ocular findings in victims of shaken baby syndrome. Can J Ophthalmol 2001; 36:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/50\">",
"      Gnanaraj L, Gilliland MG, Yahya RR, et al. Ocular manifestations of crush head injury in children. Eye (Lond) 2007; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/51\">",
"      Gleckman AM, Evans RJ, Bell MD, Smith TW. Optic nerve damage in shaken baby syndrome: detection by beta-amyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 2000; 124:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/52\">",
"      Hettler J, Greenes DS. Can the initial history predict whether a child with a head injury has been abused? Pediatrics 2003; 111:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/53\">",
"      Agrawal S, Peters MJ, Adams GG, Pierce CM. Prevalence of retinal hemorrhages in critically ill children. Pediatrics 2012; 129:e1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/54\">",
"      Gilliland MG, Luckenbach MW, Chenier TC. Systemic and ocular findings in 169 prospectively studied child deaths: retinal hemorrhages usually mean child abuse. Forensic Sci Int 1994; 68:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/55\">",
"      Buys YM, Levin AV, Enzenauer RW, et al. Retinal findings after head trauma in infants and young children. Ophthalmology 1992; 99:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/56\">",
"      Goldman M, Dagan Z, Yair M, et al. Severe cough and retinal hemorrhage in infants and young children. J Pediatr 2006; 148:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/57\">",
"      Sandramouli S, Robinson R, Tsaloumas M, Willshaw HE. Retinal haemorrhages and convulsions. Arch Dis Child 1997; 76:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/58\">",
"      Tyagi AK, Scotcher S, Kozeis N, Willshaw HE. Can convulsions alone cause retinal haemorrhages in infants? Br J Ophthalmol 1998; 82:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/59\">",
"      Emerson MV, Pieramici DJ, Stoessel KM, et al. Incidence and rate of disappearance of retinal hemorrhage in newborns. Ophthalmology 2001; 108:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/60\">",
"      Sezen F. Retinal haemorrhages in newborn infants. Br J Ophthalmol 1971; 55:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/61\">",
"      Peyman GA, Bennett TO, Vlchek J. Effects of intravitreal prostaglandins on retinal vasculature. Ann Ophthalmol 1975; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/62\">",
"      Kaur B, Taylor D. Fundus hemorrhages in infancy. Surv Ophthalmol 1992; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/63\">",
"      Christian CW, Taylor AA, Hertle RW, Duhaime AC. Retinal hemorrhages caused by accidental household trauma. J Pediatr 1999; 135:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/64\">",
"      Vinchon M, Defoort-Dhellemmes S, Desurmont M, Dhellemmes P. Accidental and nonaccidental head injuries in infants: a prospective study. J Neurosurg 2005; 102:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/65\">",
"      Reece RM, Sege R. Childhood head injuries: accidental or inflicted? Arch Pediatr Adolesc Med 2000; 154:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/66\">",
"      Johnson DL, Braun D, Friendly D. Accidental head trauma and retinal hemorrhage. Neurosurgery 1993; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/67\">",
"      Keenan HT, Runyan DK, Marshall SW, et al. A population-based comparison of clinical and outcome characteristics of young children with serious inflicted and noninflicted traumatic brain injury. Pediatrics 2004; 114:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/68\">",
"      Tzioumi D, Oates RK. Subdural hematomas in children under 2 years. Accidental or inflicted? A 10-year experience. Child Abuse Negl 1998; 22:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/69\">",
"      Sturm V, Knecht PB, Landau K, Menke MN. Rare retinal haemorrhages in translational accidental head trauma in children. Eye (Lond) 2009; 23:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/70\">",
"      Plunkett J. Fatal pediatric head injuries caused by short-distance falls. Am J Forensic Med Pathol 2001; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/71\">",
"      Yoffe G, Buchanan GR. Intracranial hemorrhage in newborn and young infants with hemophilia. J Pediatr 1988; 113:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/72\">",
"      Ryan CA, Gayle M. Vitamin K deficiency, intracranial hemorrhage, and a subgaleal hematoma: a fatal combination. Pediatr Emerg Care 1992; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/73\">",
"      Hymel KP, Abshire TC, Luckey DW, Jenny C. Coagulopathy in pediatric abusive head trauma. Pediatrics 1997; 99:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/74\">",
"      Miner ME, Kaufman HH, Graham SH, et al. Disseminated intravascular coagulation fibrinolytic syndrome following head injury in children: frequency and prognostic implications. J Pediatr 1982; 100:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/75\">",
"      Fahmy JA. Symptoms and signs of intracranial aneurysms with particular reference to retinal haemorrhage. Acta Ophthalmol (Copenh) 1972; 50:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/76\">",
"      Gutierrez Diaz A, Jimenez Carmena J, Ruano Martin F, et al. Intraocular hemorrhage in sudden increased intracranial pressure (Terson syndrome). Ophthalmologica 1979; 179:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/77\">",
"      Meyer FB, Sundt TM Jr, Fode NC, et al. Cerebral aneurysms in childhood and adolescence. J Neurosurg 1989; 70:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/78\">",
"      McLellan NJ, Prasad R, Punt J. Spontaneous subhyaloid and retinal haemorrhages in an infant. Arch Dis Child 1986; 61:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/79\">",
"      Forbes BJ, Cox M, Christian CW. Retinal hemorrhages in patients with epidural hematomas. J AAPOS 2008; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/80\">",
"      Bhardwaj G, Jacobs MB, Moran KT, Tan K. Terson syndrome with ipsilateral severe hemorrhagic retinopathy in a 7-month-old child. J AAPOS 2010; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/81\">",
"      Schloff S, Mullaney PB, Armstrong DC, et al. Retinal findings in children with intracranial hemorrhage. Ophthalmology 2002; 109:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/82\">",
"      Fahmy JA. Fundal haemorrhages in ruptured intracranial aneurysms. I. Material, frequency and morphology. Acta Ophthalmol (Copenh) 1973; 51:289.",
"     </a>",
"    </li>",
"    <li>",
"     Levin AV. Retinal hemorrahges and child abuse. In: Recent Advances in Pediatrics, David TJ.  (Ed), Churchill Livingstone, London 2000. p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/84\">",
"      Weedn VW, Mansour AM, Nichols MM. Retinal hemorrhage in an infant after cardiopulmonary resuscitation. Am J Forensic Med Pathol 1990; 11:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/85\">",
"      Gilliland MG, Luckenbach MW. Are retinal hemorrhages found after resuscitation attempts? A study of the eyes of 169 children. Am J Forensic Med Pathol 1993; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/86\">",
"      Odom A, Christ E, Kerr N, et al. Prevalence of retinal hemorrhages in pediatric patients after in-hospital cardiopulmonary resuscitation: a prospective study. Pediatrics 1997; 99:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/87\">",
"      Tomasi LG, Rosman NP. Purtscher retinopathy in the battered child syndrome. Am J Dis Child 1975; 129:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/88\">",
"      Matthews GP, Das A. Dense vitreous hemorrhages predict poor visual and neurological prognosis in infants with shaken baby syndrome. J Pediatr Ophthalmol Strabismus 1996; 33:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/89\">",
"      Levin, AV. Ocular manifestations of child abuse. Ophthalmol Clin North Am 1990; 3:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/90\">",
"      Bonnier C, Nassogne MC, Evrard P. Outcome and prognosis of whiplash shaken infant syndrome; late consequences after a symptom-free interval. Dev Med Child Neurol 1995; 37:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/91\">",
"      Wilkinson WS, Han DP, Rappley MD, Owings CL. Retinal hemorrhage predicts neurologic injury in the shaken baby syndrome. Arch Ophthalmol 1989; 107:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/92\">",
"      Harcourt B, Hopkins D. Ophthalmic manifestations of the battered-baby syndrome. Br Med J 1971; 3:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/93\">",
"      Fishman CD, Dasher WB 3rd, Lambert SR. Electroretinographic findings in infants with the shaken baby syndrome. J Pediatr Ophthalmol Strabismus 1998; 35:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/7/20602/abstract/94\">",
"      Harcourt B, Hopkins D. Permanent chorio-retinal lesions in childhood of suspected traumatic origin. Trans Ophthalmol Soc U K 1973; 93:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6612 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20602=[""].join("\n");
var outline_f20_7_20602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial eye examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ophthalmology consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OPHTHALMOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Retinal folds and retinoschisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vitreous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Optic nerve sheath hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other orbital trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSTIC IMPLICATIONS OF EYE FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Perinatal retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Unintentional head injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hematologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1270279\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Glutaric aciduria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chest compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Sudden infant death syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ophthalmologic care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6612\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6612|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35497\" title=\"figure 1\">",
"      Retinal hemorrhage types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/8/23683\" title=\"figure 2\">",
"      Superficial retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/18/21795\" title=\"figure 3\">",
"      Deep retinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/18/2339\" title=\"figure 4\">",
"      Preretinal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2150\" title=\"figure 5\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/58/16294\" title=\"figure 6\">",
"      Retinal layers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6612|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/9/12447\" title=\"picture 1\">",
"      Direct indirect opthalmoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/20/8512\" title=\"picture 2\">",
"      White centered RH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/40/10894\" title=\"picture 3\">",
"      Circular retinal fold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/62/39919\" title=\"picture 4\">",
"      Dome shaped hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/14/34030\" title=\"picture 5\">",
"      Leukemic infiltrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6612|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/33/41499\" title=\"table 1\">",
"      Ophthalmalogic dilating agents abusive head trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/39/4734\" title=\"table 2\">",
"      Retinal hemorrhage etiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7718?source=related_link\">",
"      Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=related_link\">",
"      Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9783?source=related_link\">",
"      Orbital fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36872?source=related_link\">",
"      Sudden unexpected infant death including SIDS: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32679?source=related_link\">",
"      Support services for the care of chronically ill children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_7_20603="Relative risk complication";
var content_f20_7_20603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative risk of complication using tacrolimus versus cyclosporine after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Parameter - tacrolimus versus cyclosporine",
"      </td>",
"      <td class=\"subtitle1\">",
"       RR",
"      </td>",
"      <td class=\"subtitle1\">",
"       95% CI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       One-year mortality",
"      </td>",
"      <td>",
"       0.85",
"      </td>",
"      <td>",
"       0.73-0.99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       One-year graft loss",
"      </td>",
"      <td>",
"       0.73",
"      </td>",
"      <td>",
"       0.61-0.86",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute rejection",
"      </td>",
"      <td>",
"       0.81",
"      </td>",
"      <td>",
"       0.75-0.88",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Steroid-resistant rejection",
"      </td>",
"      <td>",
"       0.54",
"      </td>",
"      <td>",
"       0.47-0.74",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Likely to change to another agent",
"      </td>",
"      <td>",
"       0.57",
"      </td>",
"      <td>",
"       0.49-0.66",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       De novo diabetes mellitus",
"      </td>",
"      <td>",
"       1.38",
"      </td>",
"      <td>",
"       1.01-1.86",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: McAlister, VC, Haddad, E, Renouf, E, et al. Cyclosporine versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20603=[""].join("\n");
var outline_f20_7_20603=null;
var title_f20_7_20604="ACC AHA ESC revert AF after 7d";
var content_f20_7_20604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC Guideline Summary: Pharmacologic cardioversion of AF &gt;7 days duration*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antiarrhythmic drug*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route of administration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Class of recommendation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Drugs proven effective",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dofetilide",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Amiodarone",
"      </td>",
"      <td>",
"       Oral or intravenous",
"      </td>",
"      <td>",
"       IIa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ibutilide",
"      </td>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       IIa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Drugs that are less effective or incompletely studied",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Disopyramide",
"      </td>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Flecainide",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Procainamide",
"      </td>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Propafenone",
"      </td>",
"      <td>",
"       Oral or intravenous",
"      </td>",
"      <td>",
"       IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Quinidine",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Drugs that should not be given",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Digoxin",
"      </td>",
"      <td>",
"       Oral or intravenous",
"      </td>",
"      <td>",
"       III",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sotalol",
"      </td>",
"      <td>",
"       Oral or intravenous",
"      </td>",
"      <td>",
"       III",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The doses of medications used in these studies may not be the same as those recommended by the manufacturers.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster, V, Ryden, LE, Cannom, DS, etal. ACC/AHA/ESC guidelines for the management of patients with atrialfibrillation. A report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the EuropeanSociety of Cardiology Committee for Practice Guidelines (Writingcommittee to revise the 2001 guidelines for the management of patientswith atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20604=[""].join("\n");
var outline_f20_7_20604=null;
var title_f20_7_20605="EORTC progn groups mesothelioma";
var content_f20_7_20605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic indices of survival for advanced mesothelioma in EORTC studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"5\" rowspan=\"1\">",
"        EORTC",
"studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Study",
"       </td>",
"       <td class=\"subtitle2\">",
"        Response (percent)",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\" rowspan=\"1\">",
"        MST",
"(months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitoxantrone",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        7.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epidoxorubicin",
"       </td>",
"       <td>",
"        13.5",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        8.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etoposide (IV)",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        6.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etoposide (PO)",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        8.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paclitaxel",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        9.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"5\" rowspan=\"1\">",
"        Poor prognostic factors in",
"multivariate analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"1\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\" rowspan=\"1\">",
"        MST",
"(months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Performance",
"status (PS)",
"       </td>",
"       <td>",
"        Good (0)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        10.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor (1-2)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        7.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        WBC count",
"       </td>",
"       <td>",
"        High (&gt;8.3)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low (&lt;8.3)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        10.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Hemoglobin (HGB)",
"       </td>",
"       <td>",
"        High* (&gt;1 g/dL)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        7.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low* (&lt;1 g/dL)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        9.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Histologic",
"diagnosis",
"       </td>",
"       <td>",
"        Definite",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        9.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Sarcomatous",
"subtype",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other subtype",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        8.4-9.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"5\" rowspan=\"1\">",
"        EORTC prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Group",
"characteristics",
"       </td>",
"       <td class=\"subtitle2\">",
"        MST (months)",
"       </td>",
"       <td class=\"subtitle2\">",
"        1 yr OS",
"       </td>",
"       <td class=\"subtitle2\">",
"        2 yr OS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Low",
"risk",
"        </strong>",
"        (prognostic score &lt;1.27)",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        10.8",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        40 percent",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        14 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\" rowspan=\"1\">",
"        Equivalent to",
"having 0-2 poor prognostic factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         High",
"risk",
"        </strong>",
"        (prognostic score &gt;1.27)",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        5.5",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        12 percent",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"2\" rowspan=\"1\">",
"        Equivalent to",
"having three or more poor prognostic factors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EORTC: European Organization for Research and Treatment of Cancer; MST: median survival time; WBC: white blood cell count, X 1000/&micro;l.",
"     <br>",
"      *&nbsp;Hemoglobin abnormalities expressed as difference relative to 16 g/dL in men and 14 g/DL in women.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20605=[""].join("\n");
var outline_f20_7_20605=null;
var title_f20_7_20606="Genetic causes of congenital diarrhea";
var content_f20_7_20606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular basis of the main forms of congenital diarrheal diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Defects of digestion, absorption, and transport of nutrients and electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Disaccharidase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Congenital lactase deficiency",
"       </td>",
"       <td>",
"        LCT",
"       </td>",
"       <td>",
"        2q21",
"       </td>",
"       <td>",
"        Lactase-phlorizin hydrolase activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sucrase-isomaltase deficiency",
"       </td>",
"       <td>",
"        EC 3.2.1.48",
"       </td>",
"       <td>",
"        3q25-q26",
"       </td>",
"       <td>",
"        Isomaltase-sucrase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Maltase-glucoamylase deficiency",
"       </td>",
"       <td>",
"        MGAM",
"       </td>",
"       <td>",
"        7q34",
"       </td>",
"       <td>",
"        Maltase-glucoamylase activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Ion and nutrient transport defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Glucose-galactose malabsorption",
"       </td>",
"       <td>",
"        SLC5A1 (SGLT1)",
"       </td>",
"       <td>",
"        22q13.1",
"       </td>",
"       <td>",
"        Na",
"        <sup>",
"         +",
"        </sup>",
"        /glucose cotransporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fructose malabsorption",
"       </td>",
"       <td>",
"        GLUT5",
"       </td>",
"       <td>",
"        1p36",
"       </td>",
"       <td>",
"        Fructose transporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fanconi-Bickel syndrome",
"       </td>",
"       <td>",
"        GLUT2",
"       </td>",
"       <td>",
"        3q26",
"       </td>",
"       <td>",
"        Basolateral glucose transporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cystic fibrosis",
"       </td>",
"       <td>",
"        CFTR",
"       </td>",
"       <td>",
"        7q31.2",
"       </td>",
"       <td>",
"        cAMP-dependent Cl",
"        <sup>",
"         -",
"        </sup>",
"        channel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Acrodermatitis enteropathica",
"       </td>",
"       <td>",
"        SLC39A4",
"       </td>",
"       <td>",
"        8q24.3",
"       </td>",
"       <td>",
"        Zn",
"        <sup>",
"         2+",
"        </sup>",
"        transporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Congenital chloride diarrhea",
"       </td>",
"       <td>",
"        SLC26A3 (DRA)",
"       </td>",
"       <td>",
"        7q22-q31.1",
"       </td>",
"       <td>",
"        Cl",
"        <sup>",
"         -",
"        </sup>",
"        /base exchanger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Congenital sodium diarrhea",
"       </td>",
"       <td>",
"        SPINT2*",
"       </td>",
"       <td>",
"        19q13.1",
"       </td>",
"       <td>",
"        Serine-protease inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Familial diarrhea syndrome",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        GUCY2C&nbsp;",
"       </td>",
"       <td>",
"        12p12.3",
"       </td>",
"       <td>",
"        Intestinal guanylate cyclase C (ligand for bacterial heat-stable enterotoxins)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lysinuric protein intolerance",
"       </td>",
"       <td>",
"        SLC7A7",
"       </td>",
"       <td>",
"        14q11",
"       </td>",
"       <td>",
"        Hydrolyzes endo-/exopeptidases, amino acid basolateral transport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Congenital bile acid diarrhea",
"       </td>",
"       <td>",
"        SLC10A2 (ABAT)",
"       </td>",
"       <td>",
"        13q33",
"       </td>",
"       <td>",
"        Ileal Na",
"        <sup>",
"         +",
"        </sup>",
"        /bile salt transporter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Pancreatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Enterokinase deficiency",
"       </td>",
"       <td>",
"        PRSS7",
"       </td>",
"       <td>",
"        21q21",
"       </td>",
"       <td>",
"        Proenterokinase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Trypsinogen deficiency",
"       </td>",
"       <td>",
"        PRSS1",
"       </td>",
"       <td>",
"        7q35",
"       </td>",
"       <td>",
"        Trypsinogen synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pancreatic lipase deficiency",
"       </td>",
"       <td>",
"        PNLIP",
"       </td>",
"       <td>",
"        10q26.1",
"       </td>",
"       <td>",
"        Hydrolyzes triglycerides to fatty acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Lipid trafficking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Abetalipoproteinemia",
"       </td>",
"       <td>",
"        MTP",
"       </td>",
"       <td>",
"        4q22",
"       </td>",
"       <td>",
"        Transfer lipids to apolipoprotein B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Hypobetalipoproteinemia",
"       </td>",
"       <td>",
"        APOB",
"       </td>",
"       <td>",
"        2p24",
"       </td>",
"       <td>",
"        Apolipoprotein that forms chylomicrons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Chylomicron retention disease",
"       </td>",
"       <td>",
"        SAR1B",
"       </td>",
"       <td>",
"        5q31.1",
"       </td>",
"       <td>",
"        Intracellular chylomicron trafficking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Defects of enterocyte differentiation and polarization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microvillous inclusion disease",
"       </td>",
"       <td>",
"        MY05B",
"       </td>",
"       <td>",
"        18q21",
"       </td>",
"       <td>",
"        Intracellular protein trafficking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital tufting enteropathy",
"       </td>",
"       <td>",
"        EpCAM",
"       </td>",
"       <td>",
"        2p21",
"       </td>",
"       <td>",
"        Cell-cell interaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syndromic diarrhea",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Defects of enteroendocrine cell differentiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteric anendocrinosis",
"       </td>",
"       <td>",
"        NEUROG3",
"       </td>",
"       <td>",
"        10q21.3",
"       </td>",
"       <td>",
"        Enteroendocrine cell fate determination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteric dysendocrinosis",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Enteroendocrine cell function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proprotein convertase 1 deficiency",
"       </td>",
"       <td>",
"        PCSK1",
"       </td>",
"       <td>",
"        5q15-q21",
"       </td>",
"       <td>",
"        Prohormone processing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Defects of modulation of the intestinal immune response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IPEX",
"       </td>",
"       <td>",
"        FOXP3",
"       </td>",
"       <td>",
"        Xp11.23-q13.3",
"       </td>",
"       <td>",
"        Transcription factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IPEX-like syndrome",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunodeficiency-associated autoimmune enteropathy",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        APS-1",
"       </td>",
"       <td>",
"        AIRE",
"       </td>",
"       <td>",
"        21p22.3",
"       </td>",
"       <td>",
"        Regulation gene transcription",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autoimmune enteropathy with colitis-GAGD",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     cAMP: cyclic adenosine monophosphate; EpCAM: epithelial cell adhesion molecule; NEUROG-3: neurogenin-3; IPEX: immune dysregulation polyendocrinopathy, enteropathy, X-linked syndrome; FOXP3: forkhead box P3; APS-1: autoimmune polyglandular syndrome-1; GAGD: generalized autoimmune gut disorder.",
"     <br>",
"      * This mutation has been associated with the syndromic form of congenital sodium diarrhea.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      References:",
"     </p>",
"     <ol>",
"      <li>",
"       Fikerstrand T, Arshad J, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. New Engl J Med 2012; 366:1586.",
"      </li>",
"     </ol>",
"     <p>",
"      All other entries in this&nbsp;table were reproduced with permission from: Canani RB, Terrin G, Cardillo G, et al. Congenital Diarrheal Disorders: Improved Understanding of Gene Disorders is Leading to Advances in Intestinal Physiology and Clinical Management. J Pediatr Gastroenterol Nutr 2010; 50:360. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20606=[""].join("\n");
var outline_f20_7_20606=null;
var title_f20_7_20607="Abnormal pancreaticobiliary junction I";
var content_f20_7_20607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal pancreaticobiliary junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP demonstrating an abnormal pancreaticobiliary junction in a child with recurrent abdominal pain and pancreatitis. Note the long, dilated common channel (thick arrow) containing a stone (thin arrow). The patient also has pancreas divisum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Topazian, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_7_20607=[""].join("\n");
var outline_f20_7_20607=null;
